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1.  BONE SUBSTITUTE 
Bone is a highly complex and specialized form of connective tissue. This tissue is 
mineralized since the organic matrix is strengthened by calcium phosphate 
crystals. Further, bone has a unique capacity for self-repair and is able to remodel 
itself according to mechanical and physiological requirements. A fracture or 
bone defect induces a cascade of tissue responses starting with the formation of 
a hematoma which contains red blood cells, platelets and a fibrin network. The 
released interleukins and growth factors recruit cells needed for bone repair. 
Under normal physiological conditions this process of bone repair will be 
sufficient to restore function in small bone defects. However, critical-sized bone 
defects or post-traumatic complications such as delayed unions, non-unions or 
mal-unions require additional bone grafting. Bone grafting is a common surgical 
procedure which is carried out in approximately 10% of all skeletal reconstructive 
surgeries to date[1]. The main function of a scaffold is to simulate the extracellular 
matrix, which, as an active biological tissue, affects cellular adhesion, migration, 
proliferation, and differentiation[2]. The use of autologous bone grafts is still 
considered the gold standard, but this treatment modality is associated with major 
disadvantages such as the limited amount of available autogenous bone as well 
as donor site morbidity. An alternative approach involves the use of allografts, 
i.e., human cadaveric bone obtained from bone banks. Allografts have been 
associated with several problems such as rejection or disease transmission. 
Synthetic bone substitutes are an emerging alternative for autografts and 
allografts. In the last decade, various types of synthetic bone grafts substitutes 
such as bioglass[3], polymers[4] and calcium phosphate (CaP) ceramics[5] or 
cements[6] have been investigated.
2. CALCIUM PHOSPHATE BONE CEMENT 
Calcium phosphate cements (CPCs) are a particularly interesting class of synthetic 
bone substitutes which exhibit chemical similarity to the mineral phase in bone 
and teeth. These inorganic cements are self-hardening, easy to handle, osteo-
conductive and osteocompatible. CPCs are prepared by mixing a precursor 
powder (calcium and/or phosphate salts) with a liquid, which initiates a 
hardening reaction. Prior to the setting reaction of CPC, the material is injectable 
and moldable followed by a hardening reaction which takes place in situ. This 
unique feature renders CPCs easy to handle from a clinical point of view. The liquid 
phase allows dissolution of the precursor salts which leads to oversaturation of 
the solution and  reprecipitation of CaP crystals. The hardening of the cement 
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takes place through entanglement of the reprecipitated needle-like or plate-like 
CaP crystals. Two types of CPCs can be discerned which form either apatite or 
brushite as end-product[7]. Both cements types have been applied successfully 
for tissue engineering purposes. However, brushite is a metastable phase at 
physiological pH and dissolves upon exposure to body fluids. In comparison to 
apatitic cement, brushite cement has a lower mechanical strength but a faster 
biodegradation. In addition, brushite cement is not biomimetic, while apatitic 
cement has a strong chemical resemblance to the mineral phase of bone tissue. 
CPC cements exhibit  excellent biocompatibility and have been used successfully 
for a broad range of clinical applications in dentistry and orthopedics since the 
early 1990s. Mechanically, CPCs have a compressive strength equal to or greater 
than bone, but a significantly lower tensile strength (1–10 MPa). Therefore, CPCs 
can be used only in non- or low-load bearing applications such as cranioplasty, 
facial contouring, and periodontal defects. Their use has also yielded good 
results in the fixation of bone fractures. However, the clinical long-term efficacy 
of CPCs is still debated, and clinical complications have been reported related to 
the mismatch of strength between bone and CPC as well as the poor degradation 
rate of apatitic CPCs [8]. 
3. POROUS APATITIC CALCIUM PHOSPHATE CEMENTS
Apatitic CPCs degrade slowly in vivo which limits subsequent ingrowth of bone 
tissue. Although the nanoporous structure of CPCs allows for fluid infiltration, 
this perfusion does not allow for migration of bone-forming cells into the cement 
matrix. Therefore, various strategies have been explored to create macroporosity 
in the cement matrix, thereby  enhancing the rate of CPC degradation and 
accelerating the rate of bone ingrowth. Foaming agents such as hydrogen 
peroxide and carbon dioxide have been used as macroporosity inducers[9-11], 
but these methods do not allow to control the size distribution of the produced 
pores. An alternative strategies involves the use of water-soluble crystals such 
as sugars or manitol[12,13]. The obtained interconnectivity can be controlled by 
the content, size and size distribution of the porogens[14]. In this way, the active 
resorption mediated by osteoclast can be enhanced which ultimately results 
into an accelerated degradation rate of the cement matrix. A more efficient 
approach is the inclusion of polymeric microparticles such as poly(D,L-lactic- 
co-glycolic) acid (PLGA) into CPCs. PLGA degrades hydrolytically leading to the 
production of acidic degradation by-products ,i.e., lactic and glycolic acid. These 
monomers acidify the local surroundings of the PLGA microparticles which 
accelerates the passive, acellular dissolution of the CPC matrix.
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4. OBJECTIVE OF THIS THESIS
The incorporation of acid-producing porogens provide more control over the 
quality and quantity of porosity by tuning the chemical and physical character-
istics of the incorporated polymeric porogens. For example, material parameters 
such as molecular weight, co-polymer composition (lactic to glycolic acid ratio), 
particle size and morphology (dense vs. hollow) can be used to tailor the 
degradation rate of these porogens. In situ degradation of polymeric porogens 
results into increased macroporosity of the CPC, thereby facilitating ingrowth of 
newly formed bone tissue. Nevertheless, the kinetics and mechanism of cement 
degradation and concomitant formation of new bone tissue following implantation 
of calcium phosphate cements containing polymeric microsphere are not yet 
fully understood. Therefore, the main objective of this thesis was to study the 
process of cement degradation and replacement by bone tissue in more detail. 
To this end, this thesis focused on the following objectives:  
1) to investigate the in vivo behavior of calcium phosphate cements containing 
microspheres composed of poly-lactic-co-glycolic acid, gelatin or polytrime-
thylene carbonate (Chapters 3 and 4);
2)  to evaluate the effect of PLGA microsphere diameter on the kinetics of bone 
formation after implantation of calcium phosphate cements containing 
polylactic-coglycolic acid microspheres (Chapter 5);
3)  to investigate the long-term in vivo osteocompatibility of apatite-forming 
calcium phosphate cements (Chapter 6) 
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1.  INTRODUCTION
The oral and craniomaxillofacial region of the human being contains several organs 
including the brains, eyes, ears, nose, and mouth, which are united into a highly 
complex structure. In addition to the essential biological functions of these organs, 
the esthetical appearance of the face is considered increasingly important in 
modern society. Generally, function and form of the underlying skeleton is 
crucial for proper functioning of organs and attractive facial appearance. 
Consequently, treatment of injury, diseases or the desire for cosmetic change 
usually requires (re)arrangement of the underlying bony tissues.
This reconstruction of bony structures in the oral and craniomaxillofacial 
region remains a clinical challenge for surgeons. In addition to the demanding 
requirements related to surgical skills and experience of surgeons, the availability 
of host-friendly and biologically-effective synthetic bone grafts called bone 
substitutes is still limited despite several decades of research. To date, the best- 
performing bone grafts are still harvested from the patient’s own body, which 
is however associated with drawbacks such as limited availability, increased 
patient morbidity, surgical creation of a donor site and risks for infection. 
Numerous synthetic bone substitutes have been developed and commercialized 
to date, but there is no consensus in the literature about an optimal formulation 
that can replace autogenous bone grafts. Generally, synthetic bone substitutes 
vary with respect to their chemical composition, physico-chemical structure 
and application form. Calcium phosphate cements (CPCs) are an emerging class 
of synthetic bone substitutes which exhibit chemical similarity to the mineral 
phase in bone and teeth. These inorganic cements are easy to handle due to their 
self-setting properties and are highly osteocompatible.  CPCs are prepared by 
mixing a precursor powder with a liquid phase, which initiates a hardening 
reaction. Prior to the setting of CPC, the material is injectable and moldable 
followed by a hardening reaction which takes place in situ. Although the 
mechanical properties of CPCs are inferior to bone tissue or highly sintered 
calcium phosphate ceramics, CPCs are highly suitable for specific applications in 
the oral and craniomaxillofacial complex, where mechanical requirements are 
less stringent. CPCs have been investigated extensively in numerous in vitro and 
in vivo studies, but information on the long-term clinical performance of CPCs 
is still scarce and inconsistent. Consequently, the purpose of this book chapter 
is to review the clinical outcome of contemporary injectable and/or moldable 
CPCs developed for the reconstruction of hard tissues in the oral and cranio-
maxillofacial region. 
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2.   ETIOLOGY OF BONE DEFECTS IN THE ORAL AND 
CRANIOMAXILLOFACIAL REGION 
Craniomaxillofacial defects that require bone grafting can be caused by: 
- infectious diseases (osteomyelitis and periodontitis)
- malignant or benign tumor surgery
- ischemic conditions after radiation therapy (osteoradionecrosis)
- traumatic injury
- developmental/congenital diseases
Depending on the severity and complexity of the damage, the treatment approach 
varies from repair to reconstruction, with different requirements related for the 
bone graft materials to be used. In the following sections, the most common 
treatments are briefly addressed.
2.1 Repair of intrabony defects caused by periodontitis
Periodontitis is an infectious disease causing loss of soft and hard tissues 
surrounding teeth. Depending on the progress and prognosis of the disease, the 
infected teeth may lose their support from the surrounding bony tissue. 
Therefore, repair of bony defects around infected teeth is an important aspect of 
the therapy in addition to treatment of the infection. To this end, various bone 
substitutes can be used to guide bone regeneration (GBR) into the defect area, 
usually assisted by the use of membranes [1].
2.2 Preservation of the alveolar volume after tooth extraction
Tooth extraction is the most commonly performed surgical intervention in the 
field of dentistry to date. Approximately 40% ~60% of the initial alveolar bone 
volume is lost 6 months after tooth extraction [2]. When multiple teeth are 
extracted in the same area, bone resorption increases even more [3]. Insufficient 
alveolar bone volume at an implant site can inhibit placement of dental implants 
in an optimal position that support the final prosthetic reconstruction. In both 
the maxillary and mandibular region, biomaterials have been used to maintain 
as much clinical volume as possible [4]. This can be achieved by e.g. GBR using 
particulate autografts, allografts, alloplasts and/or xenografts with or without 
the additional support of resorbable or non-resorbable membranes. 
2.3 Reconstruction of an atrophic alveolar ridge
Bone volume and the corresponding clinical contour change significantly after 
loss of teeth. Especially in the maxilla, the resulting atrophic alveolar ridge often does 
not allow for treatment with implants due to a lack of bone volume. To facilitate 
implant placement, the alveolar ridge often requires bone augmentation both in 
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vertical and horizontal dimensions. At least five methods towards augmentation 
of the alveolar ridge can be discerned including i) guided bone regeneration 
(GBR), ii) bone splitting or spreading to expand the ridge, iii) inlay bone grafts, 
iv) onlay bone grafts, and v) distraction osteogenesis. Several procedures such 
as GBR, onlay and inlay grafts can be performed using bone substitutes, 
membranes, or a combination thereof [5, 6]. Distraction osteogenesis is a 
clinically accepted technique, but the long time needed for distraction and the 
discomfort of the intraoral distractor are major disadvantages [7, 8]. In general, 
onlay or inlay techniques which require an additional operation at a donor site 
are more efficient in case of challenging conditions such as vertical augmentation 
of the alveolar ridge. At the area of the posterior maxilla, placement of implants is 
particularly complicated. At this anatomical site, bone can be augmented using a 
specific surgical technique called sinus augmentation (also referred to as sinus 
lifting or sinus floor elevation).
2.4   Reconstruction of large defects caused by trauma or  
traumatic therapy
The craniomaxillofacial complex can be damaged severely by trauma or traumatic 
therapies such as surgery. In these cases, dentofacial deformity, post-traumatic 
bone defects, or postoperative contour irregularities are common symptoms. 
Depending on the complexity of damage, intensive reconstructive procedures 
are often required to restore oral function and esthetics.
2.5   Cosmetic surgery for developmental/congenital diseases at  
the craniomaxillofacial region
Genetic deformities such as a cleft lip or palate, hemifacial macrosomia and 
hemifacial atrophy are indications for repair and reconstruction of the 
craniofacial region. In these clinical cases, injectable bone substitutes, which 
can be applied less invasively are generally preferred in view of the final 
prognosis and final cosmetic appearance.
3.  INJECTABLE CPCS FOR RECONSTRUCTION OF THE ORAL AND 
CRANIOMAXILLOFACIAL REGION
Injectable and/or moldable bone substitutes used in craniomaxillofacial surgery 
include cements, pastes, putties and hydrogels. This book chapter focuses on the 
use of calcium phosphate based cements.
Calcium phosphate cements (CPCs) can be categorized according to the end 
product of the setting reaction, i.e., apatite or brushite. [9]. Since their invention 
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in the early 1980s, several apatite- and brushite-forming CPCs have been 
commercialized including BoneSource®, Calcibon®, ChronOS Inject®, HydroSet® 
and Norian SRS®[10]. Frequently, carbonate substitutes for hydroxyl groups in 
apatitic cements, thereby creating cements with a higher degree of similarity to 
the mineral phase of human bone, which contains a considerable amount of 
carbonate ions.
4.   CLINICAL OUTCOME OF CPCS IN RECONSTRUCTION OF  
THE ORAL AND CRANIOMAXILLOFACIAL REGION
The following section provides a concise overview of literature between 1990 
and 2016 on the clinical outcome of the use of injectable CPCs for the reconstruction 
of the oral and craniomaxillofacial region.
4.1 Reconstruction of periodontal intrabony defects
The first human clinical trial using CPC for periodontal treatment was reported 
by Brown et al. in 1998 [10]. In this study, apatite-forming cement was applied in 
the clinically challenging indication of vertical bony defects after initial 
periodontal therapy in comparison to the application of demineralized freeze- 
dried bone allograft particles. The clinical performance of apatite cement 
was inferior to the usage of demineralized allograft particles. In this study, 
16 patients were enrolled and the observation time was 12 months [11]. In 2008, 
a randomized clinical trial conducted by Shirakata et al.  also confirmed that a 
commercially available calcium phosphate cement called Norian PDC was not 
superior to routine therapy by open flap debridement for the treatment of 
periodontal intrabony defects [12]. The lack of a favorable biological effect of 
CPC in these studies was related to i) a lack of sufficient flexural strength, ii) 
a lack of sufficient porosity in the hardened apatite cement to allow bone 
ingrowth, and iii) bacterial contamination and colonization of the implant 
surface and micropores [10]. It has to be emphasized that The setting behavior 
of CPCs is crucial for its application, as indicated by the positive outcome of 
a clinical study using a newly developed washout-resistant type of CPC in 
comparison to hydroxyapatite ceramic granules to treat human periodontal 
intraosseous defects [13]. Still, the body of evidence for the use of CPC in 
periodontology is limited due the lack of well-designed, randomized clinical 
trials.
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4.2 Extraction socket preservation 
Currently, no report exists on the application of CPCs to fill extraction sockets 
for bone volume preservation. Nevertheless, in case of placement of implants 
after extraction, CPCs are promising candidates to fill the mismatch between 
the shape of the implant surface and the socket wall, thereby replacing buccal 
bone damaged or lost during extraction [14]. A randomized clinical control study 
[15] showed that the use of a putty synthetic bone graft in combination with 
immediate implant placement can be considered as a safe, effective, and 
predictable treatment option for preserving bone- and clinical volume [16]. The 
material provided rigid support for immediately placed implants and reduced 
soft tissue tension, thereby facilitating wound closure by suturing around the 
abutments to prevent exposure of the bone substitute to contamination. 
Nevertheless, no histological evidence was provided to confirm that this putty 
bone substitute was be replaced by natural bone.
4.3 Augmentation of the maxillary sinus
In 2000 Mazor et al. first reported a preliminary study where CPC was used to 
stabilize cylindrical hydroxyapatite-coated dental implants placed simultaneously 
during the augmentation of the maxillary sinus. In total, ten patients were 
enrolled and all implants were clinically found to be osseointegrated.   Patients 
received fixed implant-supported prostheses and the mean follow-up time was 
18 months (ranging from 12 to 24 months) with high success and survival rates 
[17]. On the other hand, the clinical study of Sverzut et al. [17] provided 
conflicting results. In this study BoneSource® was used as filling material for 
maxillary sinus lifting followed by placement of implants after 9 months of 
healing. Although patients did not have postoperative complications and the 
cement was shown to be biocompatible, the authors stated that the cement was 
friable during instrumentation and installation of the dental implant. In view of 
these results, the authors concluded that it was too risky to place implants due 
to a lack of sufficient bone formation throughout the biomaterials, which was 
confirmed by subsequent examination of biopsies [18].  Sverzut et al. pointed out 
that the failure was most likely related to the lack of porosity for ingrowth of 
new bone tissue, insufficient height of residual bone (less than 5 mm) and lack of 
vascularization inside the CPC. It has to be noticed that in the study by Mazor et 
al., the implants were installed simultaneous with the sinus lifting procedure, 
which can have provided mechanical support to the applied CPC.
4.4 Augmentation of the atrophic alveolar ridge
For this application, the atrophic alveolar ridge is first splitted into two segments 
and subsequently the CPC is applied as inlay filler between both segments. 
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Thereafter, these segments are firmly fixed by either titanium miniplates or 
dental implants. In this way, it was found that the vertical dimension of the 
alveolar could be increased up to 5-7 mm (see fig.1a,b)[19]. This sandwich 
technique seems to be reliable since the initial fixation and subsequent 
protection of the CPC from mastication is ensured. In a more challenging 
approach, CPC can also be used as onlay augmention. Generally, bone healing is 
challenging for such procedures, since the load-bearing capacity of CPC - needed 
to provide mechanical resistance to mastication forces - is limited due to its 
intrinsic brittleness. Nevertheless, cases of successful reconstruction of large 
defects in the mandible caused by odontogenic keratocysts and using large 
amounts of Norian SRS as onlay materials have been reported (see fig.2a,b) [20] 
[21].
4.5 Reconstruction of the craniofacial region
Frequently used commercial CPCs such as BoneSource, Mimex® and Norian® 
have been clinically applied in the craniofacial complex for several decades. 
Clinical use of CPCs in this region is restricted to non-load-bearing areas, 
Figure 1a  Surgical procedure related 
to vertical mandible reconstruction. 
Figure 1b  Postoperative panoramic 
examination after augmentation of 
the atrophic alveolar ridge. 
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including reconstruction of full-thickness cranial defects [22], frontal and 
temporal contouring [23-25], onlay grafting for augmentation and smoothing 
contours of skeletal irregularities [26, 27], facial bone fracture [28, 29], nasal 
augmentation [30, 31] or secondary craniofacial contouring [32, 33]. In these 
cases, CPCs can be applied as moldable substitutes and sculpted into the desired 
shape. Various studies reported promising results with success rates as high as 
94% after 6 years follow-up upon evaluation by clinical examination and 
computed tomographic scans. Hydroxyapatite cement was shown to be both 
biocompatible and resistant to infection when used in sites not contiguous with 
sinus mucosa [34]as well as did the cement not cause an adverse effect on skull 
development after closing small cranial defects in pediatric patients [35]. 
On the other hand, complications are often unacceptably high when CPCs are 
used for large craniofacial full-thickness defects [36, 37]. Although the U.S. Food 
and Drug Administration has approved the use of calcium-based cements for 
Figure 2a  Intraoperative view of 
inferior border of mandible prior to 
application of injectable calcium 
phosphate cement. 
Figure 2b  Intraoperative photograph 
showing injectable calcium phosphate 
bone cement filling the void created 
by the lesion. 
Processed on: 10-4-2017
509124-L-bw-Liao
26
bony defects of up to 25 cm2, special caution should be taken when surgeons are 
treating defects of this size. In challenging conditions such as large full-thickness 
cranial defects, CPCs should be used in combination with reinforcements such as 
tough frames or meshes, such as polylactic acid (PLA) sheets [38], resorbable 
meshes [39], tantalum [40] or titanium meshes and plates [33] or reconstruction 
aided by rigid fixation [41]. Usually, these large amounts of CPC hardly resorb, 
as confirmed by biopsies taken in reoperations after major complication. In 
addition, microfragmentation of the cement were often observed inside the 
recipient site, while the amount of bone replacement was only limited to the 
peripheral area of the materials. The amount of vascularized bone tissue inside 
the set CPC was generally very low [42], while the CPC was prone to infection, 
especially in case of acute adverse events such as seroma and cellulitis formation 
after surgery. For these clinical situations, the use of CPC loaded with antibiotic 
agents, such as cephalothin, was suggested [43, 44].
It should be emphasized that complications associated with the use of CPC 
should be considered in the context of the clinical complexity of craniofacial 
reconstruction. CPC should never be used in challenging conditions such as 
defects larger than 25 cm2, defects in irradiated areas as well as defects with 
insufficient soft tissue cover. Besides these challenging conditions, injectable 
CPC can still be considered as favorable alloplasts for the reconstruction of 
craniofacial area when applied with caution [45, 46].
5. CONCLUSION AND OUTLOOK
Injectable calcium phosphate cements (CPCs) are highly useful for reconstruction 
of bone defects in the oral and craniomaxillofacial region. The evidence for 
successful application of CPC is, however, not unambiguously shown for all 
clinical indications. Consequently, prospective long-term clinical studies are 
needed to obtain insight in the long-term behavior of CPC in human patients. 
These clinical studies have to form the basis of further improvements of the 
material properties of CPCs In that respect, the main surgical priority is to 
develop CPC that allows for the creation of sufficient mechanical stability at the 
recipient site - even in non-load-bearing skeletal sites. In addition, prevention 
of pathologic contamination is of utmost importance for successful clinical 
performance of injectable CPC.
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INTRODUCTION
Most of the currently available calcium phosphate cements (CPCs) convert after 
application in a bone defect into apatite, which is a calcium phosphate phase that 
is similar to the inorganic part of bone. A disadvantage of this end-product is its 
high stability and therefore this material shows only a slow osteoclast depending 
resorption in time(1). Although, a faster degrading brushite cement(2-3) can be 
selected to solve this problem, another approach is the introduction of 
macroporosity(4) into the apatite cement. The consequential increase of surface 
area results in an increased resorption of the cement. Macroporosity can be 
generated by the addition of foaming agents to the cement such as sodium 
bicarbonate(5-6), bovine serum albumin(7), water solvable crystals(8) and by the 
introduction of biodegradadable microspheres(9-11). This last method has the 
advantage that the mechanical strength of the microspheres contributes to the 
initial strength of the ceramic scaffold(12). Additionally, these microspheres can 
be applied as drug delivery vehicle for osteoinductive growth factors(10). 
Previous studies have already shown that indeed injectable and setting CPCs 
can be produced upon the introduction of microspheres composed of poly-
(lactic-co-glycolic acid) (PLGA)(12), gelatin(13) and poly(trimethylene carbonate) 
(PTMC)(14). In vitro incubation of these composites in phosphate buffered saline 
or enzyme containing media(12, 14, 15) results in an interconnected, macroporous 
calcium phosphate matrix after microsphere degradation. The in vitro degradation 
mechanisms of the different microsphere/calcium phosphate formulations in 
these studies were varied by using polymers with unique degradation or erosion 
mechanisms (Table 1). For example, gelatin and PTMC microsphere/CPC 
composites(14, 15) were found to show a gradual degradation of the microspheres 
from the outer to the inner parts of the composite as the cement delays enzyme 
diffusion through the material. On the other hand, in PLGA microsphere containing 
cements(12), microspheres degraded concomitantly through the cement as a 
result of hydrolytic cleavage of the polymer chains. Furthermore, compared to 
the bulk erosion mechanism of PLGA and gelatin microspheres(12, 15), surface 
erosion of the PTMC microspheres(14) resulted in a fast decrease of compression 
strength as they detached from the cement skeleton. In an in vivo situation, 
conditions are different regarding fluid flow, buffer capacity and enzyme 
activity(16), and therefore it can be hypothesized that the microsphere 
composites degrade then in a different manner . 
The goal of this study was to investigate the in vivo degradation behavior 
and tissue response of microsphere/calcium phosphate cement composites 
(microsphere CPCs) with different microsphere degradation and erosion 
mechanisms. As a model, microsphere CPCs composed of calcium phosphate 
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cement containing either PLGA microspheres, gelatin microspheres or PTMC 
microspheres were formulated and implanted subcutaneously in the back of 
New Zealand white rabbits. Furthermore, to investigate the influence of the type 
of gelatin, both porcine (type A) and bovine (type B) gelatin microspheres were 
introduced into the cement. PTMC microspheres with a molecular weight of 40.0 
kg×mol-1 and 444.2 kg×mol-1 were incorporated into the cement as previous 
experiments(17) showed that higher molecular weight PTMC exhibits a higher 
erosion rate. Finally, also a composite of cement with incorporated gelatin and 
PLGA microspheres was formulated to investigate whether the degradation of 
one type of microspheres influenced the degradation of the other type of 
microspheres. 
MATERIALS AND METHODS
Materials
Poly(lactic-co-glycolic acid) (PLGA, L/G : 54/46, Mn = 34.7 kg×mol-1, Mw = 54.2 
kg×mol-1, PDI = 1.56, Purac, Gorinchem, The Netherlands), gelatin (porcine (type 
A): pI = 7.0-9.0; bovine (type B): pI = 4.5-5.0, both Acros, Geel, Belgium) and 
poly(trimethylene carbonate)(17) (LMW PTMC: Mn = 40.0 kg×mol-1, Mw = 68.7 
kg×mol-1, PDI = 1.72, HMW PTMC: Mn = 444.2 kg×mol-1, Mw = 599.0 kg×mol-1, PDI 
=1.35) were used for the preparation of the microspheres. The calcium phosphate 
cement (Calcibon®, Biomet Merck, Darmstadt, Germany) is commercially 
available and consists of 61% α-TCP, 26% DCPA, 10% CaCO3 and 3% pHA. The 
applied cement liquid was a 1% w/v Na2HPO4 solution in demineralized water 
(ddH2O). 
Methods
Preparation of PLGA microspheres
PLGA microspheres were prepared by a water-in-oil-in-water (w/o/w)-double 
emulsion solvent evaporation technique(18). 1.0 g of PLGA was dissolved in 4 ml 
of dichloromethane (DCM) in a 50 ml glass test tube. 500ml of demineralized 
water (ddH2O) was added while vortexing vigorously for 1 min, subsequently 
Table 1  Degradation/erosion pattern biodegradable polymers
PLGA Gelatin PTMC
Degradation Hydrolysis Enzymatic Enzymatic
Erosion Bulk erosion Bulk erosion Surface erosion
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adding 6 ml of a 0.3% w/v poly(vinyl alcohol) (PVA) solution in ddH2O and 
continuing vortexing for another 1 min. The content of the tube was transferred 
to a 1000 ml beaker and stirred by a magnetic stirring bar, followed by adding 
another 394 ml of 0.3% PVA and 400 ml of a 2% isopropyl alcohol (IPA) solution. 
The suspension was stirred for 1 hr, the formed microspheres were allowed to 
settle for 15 min and the solution was decanted. The remaining suspension was 
centrifuged and the microspheres were washed three times with ddH2O. Finally 
the microspheres were frozen, freeze-dried for 24 hr (-40°C, 0.13 mbar) and 
stored under argon at -20°C.
Preparation of gelatin microspheres
Gelatin microspheres were prepared using an established technique(19). Briefly, 
2.5 g of gelatin type A (GELA) / gelatin type B (GELB) was dissolved in 25 ml 
ddH2O at an elevated temperature (30 min at 60°C). The resulting clear solution 
was added slowly (10 ml pipette) to a 250 ml three-necked round bottom flask 
containing 125 ml olive oil (Acros) while stirring at 500 rpm (Teflon upper 
stirrer). The round bottom flask was cooled using an ice bath and after 30 min, 
50 ml of chilled acetone (4°C) and glutaraldehyde (0.5 ml = 6.25 mM) was added 
gently. The solution was stirred for another 1h, after which the microspheres 
were collected by filtration (paper filter, D3, Schott Duran, Mainz, Germany) and 
washed several times with acetone (~1 L) to remove residual olive oil. Thereafter, 
the microspheres were stored in a vacuum exicator.
Preparation of PTMC microspheres
PTMC microspheres were prepared by a single emulsion method(20). 1% w/v of 
HMW PTMC and respectively 2% w/v of LMW PTMC solutions in dichlorometh-
ane were emulsified in an aqueous phase containing 2% PVA. The stirring speeds 
were respectively 1000 rpm and 800 rpm. After evaporation of dichlorometh-
ane, microparticles were formed, which were purified by centrifugation and 
redispersed in the PVA-containing aqueous phase.
Preparation of microsphere/calcium phosphate cement composites
Before the microsphere/calcium phosphate cement composites were prepared, 
calcium phosphate cement powder was sterilized by gamma-irradiation (25 
kGy, Isotron, Ede, The Netherlands). Microspheres were sterilized by UV (254 
nm) to prohibit extensive degradation of the PLGA(21) or crosslinking of the 
PTMC polymer. Subsequently, cement composites were prepared and stored in a 
sterile environment. Briefly, for the preparation of the microsphere/calcium 
phosphate cement composites, (freeze-)dried PLGA microspheres or swollen 
gelatin microspheres (560 ml ddH2O/100 mg dry spheres) were mixed with the 
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calcium phosphate cement powder before liquid hardener (1% Na2HPO4) was 
added. Alternatively, PTMC microspheres were dispersed into the liquid 
hardener before adding the cement powder(14). The resulting mixtures were 
stirred vigorously for 15 s using a Silamat® mixing device (Vivadent, Schaan, 
Liechtenstein) and injected into Teflon molds with cylindrical holes (4.5 mm 
diameter, 9.0 mm length) and hardened at room temperature over night. 
Properties of the resulting calcium phosphate cement composites with PLGA 
microspheres (PLGA CPC), gelatin type A microspheres (GELA CPC), gelatin type 
B microspheres (GELB CPC), LMW PTMC microspheres (LMW PTMC CPC) and 
HMW PTMC microspheres (HMW PTMC CPC) are summarized in Table 2(12,14,15). 
In addition, a composite material was prepared which contained both PLGA and 
gelatin type A microspheres (PLGA/GELA CPC). To compare the in vivo response 
and degradation for all composites, macroporosity(4) (volume percentage of 
microspheres) was kept in the range of 48-57 %. 
Surgical procedure and implant retrieval
Eighteen 6-month old female New Zealand white rabbits of 3-4 kg were used in 
this experiment.  Surgery was performed under total anesthesia. Before surgery, 
the back of the rabbits was shaven, washed with alcohol and disinfected with 
iodine. Subsequently, at both sides of the vertical column three 1.5 cm long 
incisions were made through the full thickness of the skin. Lateral pockets for 
subcutaneous implantation were made by blunt dissection with scissors. One 
implant of each formulation was inserted into each subcutaneous pocket, after 
which the pockets were closed with Vicryl 4.0 sutures. After 4, 8 and 12 weeks, 
6 rabbits were sacrificed by CO2 suffocation. Three specimens of each material 
and time point were used for physicochemical characterization and histology. 
For physicochemical analysis, the tissue that surrounded the samples was 
removed. Then, the specimens were stored in water. For histological examination, 
samples including their surrounding tissues were fixated in a 4% formaldehyde 
solution for 1 week, dehydrated by a series of alcohol dilutions and embedded 
in methylmethacrylate. After polymerization, undecalcified 10mm thick sections 
of the implant were prepared by a modified sawing microtome technique(22). 
Three sections per implant were made and stained by methylene blue/basic 
fuchsin. 
Physicochemical analysis
Mechanical strength
After implant retrieval, wet samples were subjected to a compression strength 
measurements. Therefore, they were placed in a testing bench (858 MiniBionixII®, 
MTS Corp., Eden Prairie, MN, USA) and compression strength along the vertical 
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axis (height) of the specimens was measured at 0.5 mm/min crosshead speed. 
Samples before implantation (after 1 day setting) were used as reference.
Molecular weight
The molecular weight of the PLGA polymer inside the PLGA CPC and PLGA/GELA 
CPC at different implantation time points was measured using gel permeation 
chromatography (GPC). Therefore, samples were grinded and extracted with 3 
ml of THF. The resulting suspension was filtered using 13 mm GHP 0.2mm 
Acrodisk® filters (Waters). The HPLC system consists of a L2130 HPLC pump, a 
L-2400 UV detector and a L-2490 RI Detector (Hitachi corp., Tokyo, JPN). The 
GPC column was a 4.6*300 mm Styragel® HR 4E column with a 4.6*30 mm 
Styragel® guard column (Waters Corp., Milford, MA, USA). Tetrahydrofuran 
(THF) was used as eluent, flow rate was 0.35 ml/min. To obtain a calibration 
curve, polystyrene standards (SM-105, Shodex corp., Tokyo, JPN) were used. For 
the calculation of the number and weight average molecular weight (Mn/Mw) of 
the PLGA, Mark-Houwink constants of PLGA 50:50 (a = 0.761, K = 1.07*10-2, THF, 
22.5°C)(23) and PS (a = 0.717, K = 1.17*10-2, THF, 25°C) were used. 
Infrared spectroscopy
For the PTMC CPCs, a fraction of the samples was grinded and measured by 
attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR, 
Perkin Elmer, Fremont, CA, USA). A method derived from Featherstone et al(24) 
was used to quantitatively determine PTMC degradation of the composites in 
time and was also applied in a previous experiment(14). Briefly, the extinction of 
a characteristic PTMC peak (C=O, 1750 cm-1) and calcium phosphate peak (PO4, 
1050 cm-1) was determined using Equation 1. According to this method, the 
ratio of both extinctions (EC=O/EPO4) forms a linear relationship with the 
percentage of PTMC inside the composites. Therefore a standard curve was 
Table 2  Properties microsphere CPCs(12,14,15)
Name PLGA CPC GELA CPC GELB CPC GELA/
PLGA CPC 
LMW 
PTMC CPC 
HMW 
PTMC  CPC 
Average size 
microspheres 
(mm)
33 ± 17 37 ± 31 21 ± 15 33 ± 17,
37 ± 31
29 ± 17 15 ± 6
Wt % 
microspheres
20 % 10 % 5 % 5 + 10 % 25 % 25 %
Vol % 
microspheres
48 % 57 % 48 % 53 % 49 % 49 %
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made using samples with different PTMC/cement compositions and calibrated 
with thermogravimetric analysis (TGA). This resulted in a linear relationship 
for both LMW/HMW polymers (r2 > 0.98), which was used to determine the 
amount of PTMC in the samples. 
sample_ peak
baseline
T
T
E = log Equation 1: Extinction
Where E = extinction, Tbaseline = transmission baseline, Tsample peak = transmission 
sample peak
X-ray diffraction
The calcium phosphate cement composition of the microsphere/CPC formulations 
was determined by powder X-ray diffraction (XRD, Philips, PW 3710, Almelo, 
The Netherlands). The same grinded samples were used as for FTIR.
SEM
The morphology of the different microsphere/CPC formulations was investigated 
by scanning electron microscopy (SEM, JEOL 6400-LINK AN 10000 at 10 kV). 
Samples were dried on carbon tape and sputtered with gold prior to measurement. 
Magnifications of 250/500x were used to visualize microsphere degradation.
Histological examination
After sectioning of the histological samples, tissue response and microsphere 
degradation was examined by light microscopy (Leica Microsystems AG, 
Wetzlar, Germany). A histological grading scale for soft-tissue implants(25) was 
used to evaluate the tissue response surrounding the implant (reaction zone) 
and at the implant surface (interface) (Table 3). Two observers conducted the 
scoring separately and reached consensus on the final score. 
Statistical analysis
Data were arranged as mean ± standard deviation. Significant differences were 
determined using analysis of variance (ANOVA). Results were considered 
significant if p<0.05. Calculations were performed using GraphPad Instat® 
(GraphPad Software Inc., San Diego, Ca, USA).
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RESULTS
Implant retrieval
During the experiment one rabbit died as a result of a bacterial infection. Hence, 
of the 8 weeks group one implant of each formulation was lost. The other 
seventeen rabbits remained in a good health and did not show any wound 
complications. At the end of the implantation periods, a total of one hundred and 
two implants (17 of each formulation) were harvested. At harvesting, the 
implants were all covered by an intact fibrous tissue capsule.
Physicochemical analysis
Results of the compression strength measurements after 4, 8 and 12 weeks of 
implantation are depicted in Figure 1. In most cases compression strength 
decreased gradually during implantation time. For the PLGA CPC, PLGA/GELA 
CPC and HMW PTMC CPC, compression strength was significantly decreased 
after 12 weeks of implantation. For the GELB CPC compression strength 
significantly decreased from 11MPa initially to 4 MPa at 8 weeks of implantation, 
which was followed by a small increase in compression strength at 12 weeks. 
Table 3  Histological grading scale(25)
Evaluation Response Score
Capsule 
Quantitatively
1-4 fibroblasts 4
5-9 fibroblasts 3
10-30 fibroblasts 2
> 30 fibroblasts 1
Capsule 
Qualitatively
Capsule is fibrous, mature, not dense, resembling connective 
or fat tissue in the non-injured regions
4
Capsule tissue is fibrous but immature, showing
fibroblasts and little collagen
3
Capsule tissue is granulous and dense, containing both 
fibroblasts and many inflammatory cells
2
Capsule consists of masses of inflammatory cells with little or 
no signs of connective tissue organization
1
Interface 
Qualitatively
Fibroblasts contact the implant surface without the presence 
of macrophages or leucocytes
4
Scattered foci of macrophages and leucocytes are present 3
One layer of macrophages and leucocytes are present 2
Multiple layers of macrophages and leucocytes are present 1
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Results for gel permeation chromatography (Figure 2) show that the weight 
average molecular weight (Mw) of the PLGA polymer inside the PLGA CPC and 
PLGA/GELA CPC gradually decreased to ~ 5000 g/mol at 8 weeks of implantation. 
At 12 weeks not enough PLGA polymer was left for GPC analysis. The number 
average molecular weight (Mn) showed a similar trend (data not shown). 
Figure 1   Compression strength of samples of different microsphere/calcium 
phosphate cement formulations as a function of implantation period.
Figure 2   Weight average molecular weight of PLGA of the PLGA CPC and PLGA/
GELA CPC as a function of implantation period.
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ATR-FTIR (Figure 3) revealed that the PTMC CPCs exhibited microsphere 
degradation after 4-12 weeks as the percentage of PTMC inside the composites 
significantly decreased to ~ 70% of its original value. No significant differences 
in degradation rate were observed between both LMW/HMW PTMC CPCs. The 
spectrograms also indicated that after subcutaneous implantation an additional 
peak appeared at 1650 cm-1 corresponding to the C=O stretch of proteins(26).
In the SEM-micrographs (Figures 4-5), degradation of the PLGA was observed 
for both PLGA CPC and PLGA/GELA CPC samples as characterized by a structural 
deformation of the microspheres at 4 weeks and complete disappearance of the 
microspheres at 8 and 12 weeks of implantation. 
Figure 3   Determination of the amount of PTMC in the PTMC CPCs;  
A. IR spectra HMW PTMC CPC  of starting material and at t=12 weeks, 
B. amount of PTMC as % of initial amount of PTMC  in both LMW 
PTMC CPC  and HMW PTMC CPC scaffolds as a function of implantation 
period, *** = p<0.005.
A
B
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In the GELA CPC, GELB CPC and PLGA/GELA CPC, gelatin shells were still visible 
at 12 weeks of implantation. In time, the structural morphology of the gelatin 
microspheres changed. Initially, the microspheres had a thick shell(13, 15), but at 
8 and 12 weeks the thickness decreased slowly, which was also associated 
with deformations of the shell wall. The occurrence of gelatin degradation 
was further confirmed by the observation that at 12 weeks the composites 
showed a distinctive higher porosity than after 4 weeks (Figure 6). In all gelatin 
microsphere containing CPCs also some tissue ingrowth was observed as is 
visualized in Figures 6C and 6D.
The PTMC CPCs showed the presence of microsphere structures at all time 
points. However, microspheres were fluidized in LMW PTMC CPC. In the HMW 
PTMC CPC, the microspheres maintained a spherical structure although the 
diameter of the spheres decreased during implantation resulting in an empty 
space between the microsphere and the surrounding spherical hole. Furthermore, 
it was observed that in HMW PTMC CPC, spheres were often fused together 
Figure 4   SEM-micrographs of PLGA CPC, GELA CPC and GELB CPC samples at  
t = 0, 4 and 12 weeks of implantation (original magnification 500x).
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(Figure 7). At a fracture plane, fused HMW PTMC microspheres were found to be 
interconnected by PTMC wires, while in the LMW PTMC CPC the polymer showed 
elongation without the retention of microsphere structure.
Finally, investigation of the cement composition with XRD (Figure 8) showed 
that for all microsphere CPCs, monetite and a-TCP signals completely disappeared 
within the 12 week implantation period. 
Histological examination
Light microscopical pictures of the various histological specimens are depicted 
in Figures 9A-B. After 4 weeks of implantation, the surface of the implants 
showed a rough appearance with spherical cavities corresponding to degraded 
microspheres and irregular shaped calcium phosphate particles. Tissue response 
to all microsphere CPC/formulations was similar, and revealed a fibrous capsule 
of typically > 10 layers that was composed of aligned cells/fibroblasts. In more 
Figure 5   SEM-micrographs of PLGA/GELA CPC, LMW PTMC CPC and HMW 
PTMC CPC  after t = 0, 4 and 12 weeks of implantation (original 
magnifications 250 and 500x).
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than 50% of the samples, this fibrous capsule contained some inflammatory cells. 
Occasionally, between the fibrous capsule and cement surface multiple layers of 
inflammatory cells were observed, which could be associated with the presence 
of multi-nucleated cells at the cement surface. At places where the implant 
showed a smooth surface, less/no inflammatory response was seen. For the 
GELA CPC, GELB CPC and GELA/PLGA CPC, cells were seen in the microsphere 
cavities till a distance of >100mm below the implant surface. 
The 8 and 12 week specimens showed a gradual decrease in fibrous capsule 
thickness, especially for PLGA CPC and GELB CPC. Tissue ingrowth into the 
various microsphere/CPC formulations increased during implantation time. 
Further, tissue response at these time points was similar to the 4 weeks samples.
Figure 6   SEM micrographs of GELA CPC at t = 4 (A) and 12 weeks  
(B) of implantation, close-up picture GELA CPC at  t = 4 weeks  
of implantation (C) and SEM micrograph of PLGA/GELA CPC at t = 8 
weeks of implantation (D) (arrows denote tissue ingrowth,  
original magnifications 100x and 250x).
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Besides tissue response, some distinct differences regarding structure or 
microsphere degradation were visible with light microscopy. At t = 4 weeks all 
gelatin microsphere CPCs looked similar and microspheres were evenly spread 
throughout the material. Gelatin microspheres could be easily distinguished 
from the surrounding cement or pores because they adsorbed high quantities 
of dye. Morphology did not change for GELA CPC after t = 8 and 12 weeks, while 
for the PLGA/GELA CPC and GELB CPC the microspheres at the outer parts of 
the samples slowly degraded in time. Furthermore, for the HMW PTMC CPC, 
cement at the outer parts was fractured at all time points, while for the other 
microsphere/CPC formulations cement structure was intact. 
Figure 7   SEM micrographs LMW PTMC CPC at t=4 weeks of implantation 
indicating stretching of the material at a fracture plane  
(A + B, original magn. 1000 and 430x), agglomeration of HMW PTMC 
microspheres (C, original magn 500x) and agglomerated HMW PTMC 
microspheres at fracture interface (D, original magn 700x).
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Histological grading results are given in Figure 10. For all microsphere CPCs, 
fibrous capsule thickness scored between 2-2.5 at week 4 and appeared to show 
a gradual decrease over time. Significant differences in capsule thickness were 
found between the PLGA CPC and PLGA/GELA CPC after 8 and 12 weeks (p<0.05). 
The fibrous capsule quality was similar for most microsphere/CPC formulations 
and time points (an average scoring of 2.5), but for the GELB CPC and PLGA CPC 
a statistically slightly higher capsule quality (p<0.05) was obtained compared 
to both PTMC CPCs after 8 and 12 weeks respectively. The implant interface 
quality data showed an average score of 1.5-2.0 for all groups and time points, 
which did not change over time. Further, the interface data did not show 
significant differences between the various microsphere/CPC formulations.
Figure 8   XRD-spectra of GELB CPC featuring  cement powder, starting 
material (t=0) and samples after 4, 8 and 12 weeks of implantation.
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Figure 9A   Histological sections PLGA CPCs at 4, 8 and 12 weeks of 
subcutaneous implantation, C = cement, M = microsphere,  
F = fibrous capsule, arrows denote tissue ingrowth in  
microspheres (bar represents 25mm).
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Figure 9B   Histological sections of microsphere CPCs after 12 weeks of 
implantation; PLGA CPC (1), GELA CPC (2), GELB CPC (3), PLGA/
GELA CPC (4), LMW PTMC  CPC (5) and HMW PTMC CPC (6),  
arrows denote tissue ingrowth with GELB CPC, dashed arrow 
denotes shell gelatin microsphere (bar represents 100 mm).
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Figure 10   Histological scoring of samples after 4, 8 and 12 weeks of 
implantation; A. Capsule quantitatively, B. Capsule qualitatively,  
C. Interface qualitatively; * = p<0.05.
A
B
C
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DISCUSSION
In this study, composites of calcium phosphate cements with incorporated PLGA, 
gelatin or PTMC microspheres were implanted subcutaneously into the back 
of rabbits to investigate the in vivo degradation characteristics and to evaluate 
the biocompatibility of these materials. For in vitro degradation studies with 
microsphere/calcium phosphate cement composites macroporosity was generated 
by various microsphere degradation and erosion mechanisms after incubation 
in phosphate buffered saline (PBS)(12) or enzyme containing media(14,15). 
Although in an in vivo environment gelatin and PTMC degrading enzymes are 
present, degradation patterns can be different due to an altering fluid flow, 
buffer capacity and enzyme activity. 
Results from GPC analysis show that the molecular weight (Mn and Mw) of the 
PLGA microspheres inside the composites decreased continuously from the 
beginning, and microspheres were fully degraded within 12 weeks of 
implantation. This degradation pattern was confirmed by compression strength 
data that showed a continuous and significant decrease over time. Also the SEM 
micrographs confirmed the complete disappearance of the microsphere 
structure after 8 and 12 weeks, whereas at 4 weeks microspheres were still 
present. This result corresponds to an earlier performed in vitro degradation 
study(12) where microspheres were used with a similar molecular weight. 
Evidently, the degradation mechanism of PLGA (hydrolysis, bulk erosion) is 
therefore also valid in an in vivo environment.
For gelatin microsphere CPCs it is difficult to investigate the microsphere 
degradation because both GPC and FTIR cannot be applied. Although water-phase 
GPC is available to investigate the molecular weight of proteins, gelatin consists 
of a wide range of different molecular weights and does not give a clear Gaussian 
distribution. Holland et al(19) used the microsphere swelling characteristics to 
determine hydrogel degradation, but in the gelatin CPCs microspheres are 
trapped inside a stiff calcium phosphate matrix. In addition, FTIR cannot be 
used to investigate in vivo microsphere degradation as gelatin does not give 
sharp, distinctive peaks and the percentage (5-10wt%) of microspheres is small 
compared to the cement phase. Finally, additional proteins that are absorbed by 
the cement will give a signal at the same place (1650 cm-1) as gelatin, as was also 
visible in the FTIR-curves of HMW PTMC CPC. 
Despite the fact that it is difficult to quantify gelatin microsphere degradation 
inside these composites, the gelatin microspheres do show degradation as next 
to the decrease in compression strength, a distinct visual increase in porosity of 
the composite was observed in SEM. Histological examination provided a better 
indication of the degradation mechanism for both GELB CPCs and PLGA/GELA 
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CPCs. It was observed that microsphere degradation proceeded from the outside 
to the center of the material, which corresponds to the in vitro degradation 
mechanism(15). However, it has to be noticed that GELA CPC did not show this 
degradation pattern, as probably caused by the overall thicker shell of these 
microspheres, which is more difficult to degrade completely. Apparently, the 
combination of GELA and PLGA microspheres improves the GELA microsphere 
degradation. This can be due to the higher porosity as generated after PLGA 
microsphere degradation that improves enzyme diffusion into the composite. 
Furthermore, histological evaluation and investigation by SEM confirmed the 
ingrowth of cells at a distance of >100 mm into the GELA CPC, GELB CPC and 
PLGA/GELA CPC composites, which indicates that the porosity generated by the 
microspheres was interconnected(27). Nevertheless, cell ingrowth never reached 
the center of the implant as was observed by Link et al(28) with PLGA CPC.  A too 
small size of the PLGA microspheres(28) or the formation of calcium phosphate 
precipitate in or onto the gelatin microspheres(13, 15) can have hampered inter-
connectivity of the pores in our study, thereby prohibiting tissue ingrowth. 
Analysis with FTIR revealed that both LMW PTMC CPCs and HMW PTMC CPCs 
showed microsphere degradation as the percentage of PTMC inside the composites 
significantly decreased after subcutaneous implantation. Furthermore, SEM- 
investigation showed that the HMW PTMC microspheres became smaller than 
the surrounding spherical hole, which indicates the occurrence of surface 
erosion of the microspheres. 
No significant differences in degradation rate between the LMW PTMC and 
HMW PTMC were observed and both formulations exhibited about 30% 
degradation at 12 weeks of implantation. Alternatively, studies by Zhang et al(17) 
where PTMC disks were implanted in the femur and tibia of rabbits, have shown 
that the highest molecular weight PTMC exhibits a faster in vivo degradation as 
the enzymes (lipases) degrade hydrophobic polymers, i.e. ones with higher 
molecular weights, faster than the lower molecular weight polymers. In a 
previous in vitro degradation experiment with PTMC CPCs in lipase solution(14), 
the highest molecular weight polymer microspheres (PTMC176, Mn = 176 kDa) 
degraded even slower than the lower molecular weight microspheres (PTMC53, 
Mn = 53 kDa). The explanation for this observation was that the presence of a 
hydrophilic layer of poly(vinyl alcohol) (PVA) at the surface of the microspheres 
delayed PTMC degradation of the smaller HMW PTMC microspheres. In our 
study, the difference between the low and high molecular weight PTMC polymer 
was larger (40 kDa to 444 kDa), which evidently improved the degradation of 
the HMW PTMC microspheres. Alternatively, also a different environment or 
enzyme sources could have influenced the in vivo degradation of these PTMC 
CPC composites.
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Light microscopical analysis revealed that the outer parts of the HMW PTMC 
CPC histological samples were fractured at all time points, whereas this was not 
observed with SEM investigation. To investigate whether this phenomenon is a 
result of in vivo microsphere degradation or the histological embedding 
procedure, additional analysis was performed. Therefore, a freshly made HMW 
PTMC CPC sample was exposed to each step of the embedding procedure and 
subsequently analyzed by m-CT (data not shown). Results showed fracturing 
of the sample after it was put in acetone for 4h. This step is normally performed 
to remove fatty tissue from the sample before embedding it in MMA, but in 
this case the acetone swelled the HMW PTMC microspheres and forced the 
surrounding cement to fracture. Furthermore, it only occurred at the outer 
parts of the sample as the acetone was not completely penetrating into the 
composite. 
In agreement with our previous in vitro degradation experiment, elongation of 
microspheres at a fracture surface was observed in SEM-micrographs(14). For 
the HMW PTMC CPCs, also agglomeration of the microspheres was observed. 
This is beneficial for tissue ingrowth as interconnections between pores will be 
present after microsphere degradation. However, it explains also the low initial 
compression strength when compared to the other microsphere CPCs as the 
resulting cement skeleton will be weaker.
Finally, the histological grading data revealed that especially the implant 
interface of all microsphere/CPC formulations showed a moderate inflammatory 
response as inflammatory cells were present between the fibrous tissue capsule 
and cement surface. This was in contrast to previous studies where CPC(29) 
or PLGA CPC(28) was subcutaneously implanted in goats as well as rats and only 
a limited inflammatory response was observed. The thickness of the fibrous 
capsule, however, was similar to these studies. An explanation for the higher 
inflammatory response at the implant interface can be found in the irregular 
shaped surface of the microsphere/calcium phosphate cement composites(29) 
as caused by microsphere degradation. Also the animal model can influence the 
inflammatory response as the morphology of the skin and subcutaneous tissue 
of the rabbit are different compared with the rat and goat. Furthermore as all 
composites showed a similar tissue response, products of the microspheres like 
lactic acid, gelatin(30) or glutaraldehyde(31) did evidently not contribute to the 
inflammatory response to a high extent.
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CONCLUSION
Composites composed of calcium phosphate cement with incorporated PLGA, 
gelatin or PTMC microspheres showed in vivo degradation of the microspheres 
with corresponding decrease in mechanical strength. PLGA microspheres 
exhibited bulk erosion concomitantly through the composites, whereas with 
gelatin type B degradation of the microspheres started at the outside and 
gradually proceeded to the inner part. Furthermore, with HMW PTMC, surface 
erosion of microspheres over time was observed. Histological analysis revealed 
that for all composites a similar tissue response was observed with a decreasing 
capsule thickness over time and a moderate to significant inflammatory 
response between the fibrous capsule and cement surface. Overall, microsphere 
CPCs can be used to generate porous scaffolds in an in vivo environment after 
degradation of microspheres with various degradation/erosion mechanisms. 
Acknowledgements
Authors would like to thank Natasja van Dijk and Martijn Martens for the 
histological preparations and Vincent Cuijpers for technical assistance. 
Furthermore, authors would like to thank dr. Frank Walboomers for his help 
with histological scoring. Scanning electron microscopy was performed at the 
Microscopic Imaging Centre (MIC) of the Nijmegen Centre for Molecular Life 
Sciences (NCMLS), the Netherlands. Supported by the Dutch Technology 
Foundation STW, grant # NGT 6205.
Processed on: 10-4-2017
509124-L-bw-Liao
54
REFERENCES
1) Ooms EM, Wolke JCC, van der Waerden JP, Jansen JA. Trabecular bone response to injectable 
calcium phosphate (Ca-P) cement. J Biomed Mater Res Part A 2002; 61(1): 9-18.
2) Theiss F, Apelt D, Brand B, Kutter A, Zlinsky K, Bohner M, Matter S, Frei C, Auer JA, von Rechenberg 
B. Biocompatibility and resorption of a brushite calcium phosphate cement. Biomaterials 2005; 
26(21): 4383-94.
3) Kuemmerle JM, Oberle A, Oechslin C, Bohner M, Frei C, Boecken I, von Rechenberg B. Assessment 
of the suitability of a new brushite calcium phosphate cement for cranioplasty – an experimental 
study in sheep. J Craniomaxillofac Surg 2005; 33(1): 37-44.
4) Habraken WJEM, Wolke JGC, Jansen JA. Ceramic composites as matrices and scaffolds for drug 
delivery in tissue engineering. Adv Drug Deliv Rev 2007; 59(4-5): 234-45.
5) Del Real RP, Ooms EM, Wolke JGC, Vallet-Regí M, Jansen JA. In vivo bone response to porous 
calcium phosphate cement. J Biomed Mater Res Part A 2003; 65(1): 30-6.
6) Del Real RP, Wolke JGC, Vallet-Regí M, Jansen JA. A new method to produce macropores in calcium 
phosphate cements. Biomaterials 2002; 23(17): 3673-80.
7) Ginebra MP, Delgado JA, Harr I, Almirall, Del Valle S, Planell JA. Factors affecting the structure and 
properties of an injectable self-setting calcium phosphate foam. J Biomed Mater Res Part A 2007; 
80(2): 352-61.
8) Xu HH, Weir MD, Burguera EF, Fraser AM. Injectable and macroporous calcium phosphate cement 
scaffold. Biomaterials 2006; 27(24): 4279-87.
9) Simon Jr CG, Khatri CA, Wight SA, Wang FW. Preliminary report on the biocompatibility of a 
moldable, resorbable, composite bone graft consisting of calcium phosphate cement and poly-
(lactide-co-glycolide) microspheres. J Orthop Res 2002; 20(3): 473-82.
10) Ruhé PQ, Hedberg EL, Torio Padron N, Spauwen PHM, Jansen JA, Mikos AG. rhBMP-2 release from 
injectable poly(D,L-lactic-co-glycolic acid)/calcium phosphate cement composites. J Bone Joint 
Surg Am 2003; 85A(3): 75-81.
11) Schnieders J, Gbureck U, Thull R, Kissel T. Controlled release of gentamycin from calcium 
phosphate- poly(lactic acid-co-glycolic acid) composite bone cement. Biomaterials 2006; 27(23): 
4239-49.
12) Habraken WJEM, Wolke JGC, Mikos AG, Jansen JA. Injectable PLGA microsphere/calcium 
phosphate cemens: physical properties and degradation characteristics. J Biomat Sci Polym Ed 
2006; 17(9): 1057-74.
13) Habraken WJEM, de Jonge LT, Wolke JGC, L Yubao, Mikos AG, Jansen JA. Introduction of gelatin 
microspheres into an injectable calcium phosphate cement. J Biomed Mater Res Part A 2008; 
87(3): 643-55.
14) Habraken WJEM, Zhang Z, Wolke JGC, Grijpma DW, Mikos AG, Feijen J, Jansen JA. Introduction of 
enzymatically degradable poly(trimethylene carbonate) microspheres into an injectable calcium 
phosphate cement. Biomaterials 2008;29(16); 2464-76.
15) Habraken WJEM, Wolke JGC, Mikos AG, Jansen JA. Porcine gelatin microsphere/ calcium 
phosphate cement composites: in vitro degradation and drug release.  J Biomed Mater Res Part B 
Appl Biomat 2009; 91B(2): 555-61.
16) Holland TA, Mikos AG. Advances in drug delivery for articular cartilage. J Control Release 2003; 
86(1): 1-14.
17) Zhang Z, Kuijer R, Bulstra SK, Grijpma DW, Feijen J. The in vivo and in vitro behavior of 
poly(trimethylene carbonate). Biomaterials 2006; 27(9): 1741-8.
18) Lu L, Stamatas GN, Mikos AG. Controlled release of transforming growth factor b1 from 
biodegradable polymer microparticles. J Biomed Mater Res Part A 2000; 50: 440-51.
19) Holland TA, Tessmar JK, Tabata Y, Mikos AG. Transforming growth factor-b1 release from oligo-
(poly(ethylene glycol) fumarate) hydrogels in conditions that model the cartilage wound healing 
environment. J Control Release 2004; 94(1): 101-14.
Processed on: 10-4-2017
509124-L-bw-Liao
55
3
20) Zhang Z, Foks MA, Grijpma DW, Feijen J. PTMC and MPEG-PTMC microparticles for hydrophilic 
drug delivery. J Control Release 2005; 101(1-3): 392-4.
21) Schwach G, Oudry N, Delhomme S, Luck M, Lindner H, Gurny R. Biodegradable microparticles for 
sustained release of a new GnRH antagonist—part I: Screening commercial PLGA and formulation 
technologies. Eur J Pharm Biopharm 2003; 56: 327.
22) Klein JP, Sauren YM, Modderman WE, van der Waerden JP. A new saw technique improves 
preparation of bone sections for light and electron microscopy. J Appl Biomater 1994; 5: 369-73.
23) Schwartz K, Epple M. A detailed characterization of polyglycolide prepared by solid-state poly-
condensation reaction. Macromol Chem Phys 1999; 200(10), 2221-9.
24) Featherstone JDB, Pearson S, LeGeros RZ. An Infrared method for quantification of carbonate in 
carbonated apatites. Caries Res 1984; 18: 63-6.
25) Jansen JA, Dhert WJ, van der Waerden JP, von Recum AF. Semi-quantitative and qualitative 
histologic analysis method for the evaluation of implant biocompatibility. J Invest Surg 1994; 7: 
123-34.
26) Pouchert CJ (Editor). The Aldrich library of infrared spectra Edition III. 1981 page 435
27) Karageorgiou V, Kaplan D. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials 
2005; 26: 5474-91.
28) Link DP, van den Dolder J, Jurgens WJ, Wolke JG, Jansen JA. Mechanical evaluation of implanted 
calcium phosphate cement incorporated with PLGA microparticles. Biomaterials 2006; 27(28): 
4941-7.
29) Ooms EM, Egglezios EA, Wolke JGC, Jansen JA. Soft tissue response to newly developed calcium 
phosphate cements. Biomaterials 2003; 24: 749-57.
30) Venien A, Levieux D. Differentiation of bovine from porcine gelatins using polyclonal anti-peptide 
antibodies in indirect and competitive indirect ELISA. J Pharm Biomed Anal 2005; 39: 418-24.
31) Liang HC, Chang WH, Lin KJ, Sung HW. Genipin-crosslinked gelatin microspheres as a drug carrier 
for intramuscular administration: in vitro and in vivo studies. J Biomed Mater Res Part A 2003; 
65(2): 271-82.
Processed on: 10-4-2017
509124-L-bw-Liao
Processed on: 10-4-2017
509124-L-bw-Liao
Injectable calcium phosphate  
cement with PLGA, gelatin  
and PTMC microspheres in  
a rabbit femoral defect 
Hongbing Liao abd
X. Frank Walboomers a
Wouter J.E.M. Habraken a
Zheng Zhang c
Yubao Li d
Dirk W. Grijpma ce
Antonios G. Mikos f
Joop G.C. Wolke a
John A. Jansen a*
4
a   Department of Biomaterials, Radboud University Nijmegen Medical Centre, P.O. Box 9101,  
6500HB Nijmegen, the Netherlands 
b   College of Stomatology, Guangxi Medical University, People Republic of China 
c   Institute for Biomedical Technology and Department of Polymer Chemistry and Biomaterials,  
Faculty of Science and Technology, University of Twente, the Netherlands 
d   Centre for Nano-Biomaterials, Sichuan University, People Republic of China
e   Department of Biomedical Engineering, University Medical Centre Groningen and  
University of Groningen, the Netherlands
f   Department of Bioengineering, Rice University, Houston, Texas, USA
Acta Biomaterialia 2011; 7:1752-9.
Processed on: 10-4-2017
509124-L-bw-Liao
58
Processed on: 10-4-2017
509124-L-bw-Liao
59
4
1.  INTRODUCTION 
Calcium phosphate ceramics are generally accepted as bone restorative materials[1], 
and usually applied in the form of blocks or granules. Unfortunately, the clinical 
application of these materials is associated with impediments regarding defect 
filling and material retention: perfect filling of a bone defect with ceramic blocks 
is not possible, while granulate material is able to migrate into the surrounding 
tissue[2]. To overcome this problem, calcium phosphate cements (CPCs) have 
been developed. CPCs consist of a powder containing solid compounds of calcium 
phosphate salts and an aqueous liquid. Mixed in an appropriate ratio a paste is 
formed, which sets at room temperature by entanglement of the crystals 
precipitating within the paste. CPCs can be injected to perfectly fill the defect 
dimensions, and set in situ [3-5]. Further, CPCs are considered to be extremely 
biocompatible and show fast deposition of new bone on their surface [6]. One of 
the main disadvantages is the slow degradation rate of the material. Consequently, 
previous studies focused on the introduction of macroporosity in the cements 
[7-8]. These studies showed that macroporous CPCs can be produced by mixing 
the solid calcium phosphate salts with polymeric microspheres (e.g. poly(lac-
tic-co-glycolic acid) (PLGA), gelatin or poly(trimethylene carbonate) (PTMC) 
[9-12]. In vitro results showed that PLGA microspheres incorporated into CPCs 
were degraded completely in 6-12 weeks. It was found that the degradation rate 
is influenced by the physicochemical properties of the PLGA, including molecular 
weight, lactic to glycolic acid ratio, particle size and structure. During the 
degradation of the PLGA particles, an increased macroporosity of the CPC lead to 
ingrowth of bone, when implanted in cranial defect in rats[13]. Additionally, an 
excellent osteocompatibilty was observed, while the formed pores subsequently 
allowed complete ingrowth of hard tissue throughout the entire specimen after 
12 weeks of implantation [13]. Still, a limitation regarding the use of PLGA is the 
relatively slow degradation of the microparticles (6-12 weeks). Therefore, 
enzymatically degrading polymers (e.g. gelatin and PTMC) were introduced into 
the cements. It was found that besides faster degradation, enzymatic degradation 
also affects the degradation profile of the CPC/polymer composite. Instead of a 
hydrolytic cleavage of the PLGA microspheres [14], gelatin[11] and PTMC are 
presumed to show a gradual breakdown as the degrading enzymes penetrate 
into the CPC matrix [12,15]. In a recent in vivo study, these composite CPCs 
showed a similar tissue response when implanted subcutaneously in the back of 
rabbit[16]. For experimental reasons, the composite CPCs could not be applied 
as a paste, but were implanted as preset discs.
To date, only limited data is available regarding injectable composite CPCs used as 
a bone substitute material. It can be hypothesized that the degradation behavior 
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of composite CPCs depends on both site of implantation (subcutaneous vs. osseous 
site) and formulation (in situ setting paste vs. preset disc). In view of that, the 
purpose of the present study was to evaluate the in vivo degradation and tissue 
response towards injectable, composite CPCs that contain either PLGA, gelatin, or 
PTMC microspheres using a rabbit femoral condyle implantation model.
 
2. MATERIALS AND METHODS
2.1 Materials
Poly(lactic-co-glycolic acid)(PLGA) (Mn = 34.7 kg/mol, Mw = 54.2kg/mol, poly-
dispersity index (PDI)=1.56, lactic to glycolic acid ratio (L/G)=54:46; Purasorb®, 
Purac, Gorinchem, the Netherlands), gelatin (porcine type A) (GEL) (iso electric 
point pI=7.0-9.0; Acros, Geel, Belgium) and poly(trimethylene carbonate) (PTMC; 
synthesized as described before [15]) (Mn=444.2kg/mol, Mw=599.0kg/mol, 
PDI=1.35) were used for the preparation of the hollow microspheres.  
2.2 Preparation of CPC control and CPC/Polymer composites 
2.2.1 Preparation of CPC control
The chemical composition of the cement consisted of commercially available 
calcium phosphate powders. 85 wt./wt.% alpha-tricalcium phosphate (a-TCP) 
(CAM Implants BV, Leiden, The Netherlands), 10 wt./wt.% dicalcium phosphate 
anhydrous (DCPA) (analytical grade, J.T. Baker Chemical Co., Phillipsburg, USA) 
and 5 wt./wt.% precipitated hydroxylapatite (pHA) (Merck, Darmstadt, Germany). 
An aqueous solution of 2% Na2HPO4 (analytical grade, Merck, Darmstadt, Germany) 
was used as the liquid component. The liquid/powder ratio was 0.35 mL/g. 
Before use, the cement powder was sterilized by gamma radiation with 25 kGy 
(Isotron B.V., Ede, the Netherlands). The cement liquid was sterilized by filtration 
(Whatman®, Dassel, Germany, 0.2 μm filter).
2.2.2 Preparation of PLGA microspheres
PLGA microspheres were prepared using a water-in-oil-in-water (w/o/w) double 
emulsion solvent evaporation technique [14]. In brief 1.0 g of PLGA was solved in 
4 mL of dichloromethane (DCM) (25%wt./v.) (analytical grade, Acros, Geel, 
Belgium) followed by the addition of 0.5 mL of demineralized water (ddH2O, 
MilliQ) while vortexing vigorously for 1 min; then, 6 mL of a 0.3% w/v poly(vinyl 
alcohol) (PVA) (88% hydrolyzed, MW 22000, Acros, Geel, Belgium) solution in 
ddH2O was added and the emulsion was vortexed for another 1 min. The content 
was transferred to a stirred 1000 mL beaker, followed by adding another 394 mL 
of 0.3 wt./wt.% PVA and 400 mL of a 2% isopropylic alcohol (IPA) (analytical 
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grade, Merck, Darmstadt, Germany) solution in ddH2O. The suspension was 
stirred for 1 hr. The formed microspheres were allowed to settle for 15 min and 
the solution was decanted. The remaining suspension was centrifuged, and the 
microspheres were washed three times with ddH2O. Finally the microspheres 
were frozen, lyophilized for 24 hours (-40°C, 0.13bar) and stored under Argon 
at -20°C.
2.2.3 Preparation of Gelatin microspheres
Gelatin microspheres were prepared using an established technique[11]. Briefly, 
5 g gelatin was dissolved in 45 mL in ddH2O (11.1%wt./v.) for 30 min at 60 ºC. 
The resulting solution was added slowly into 250 mL olive oil (Acros, Geel, 
Belgium) while stirring at 500 rpm (Teflon upper stirrer). The emulsion was 
cooled in an ice bath while stirring constantly. After 30 min, 100 ml chilled 
acetone (4ºC) (analytical grade, Acros, Geel, Belgium) and glutaraldehyde 
(1mL=12.5mM) (analytical grade, Acros, Geel, Belgium) was added slowly. The 
solution was stirred for another 1 h and the formed microspheres were collected 
by filtration (7µm filter, D3, Schott Duran, Mainz, Germany) and washed with 
acetone repeatedly (approximately 1.5L) to remove residual olive oil. The micro - 
spheres were collected by filtration and vacuum dried overnight. 
2.2.4 Preparation of PTMC microspheres
PTMC microspheres were prepared by a single emulsion method [12]. Briefly 1% 
w/v of PTMC solution in DCM was emulsified in an aqueous phase containing 
2wt./wt.% PVA with a stirring speed of 1000 rpm. Microspheres were formed 
after evaporation of dichloromethane, collected microspheres were rinsed with 
water and freeze-dried.
2.2.5 Preparation of CPC/polymeric microspheres composites
After preparation all polymeric microspheres were sterilized again by UV light 
(254nm). All subsequent preparations for the in vivo studies were done aseptically; 
so no further sterilization after final production was necessary. In general, the 
preparation of all injectable CPC/polymeric microsphere composites was similar 
to the methods that had been well described in previous studies [11,12,14]. 
The mixing procedure started after the femoral defect was surgically created. 
PLGA microspheres (freeze-dried) or Gel microspheres (560μL ddH2O were 
added to 100mg dried microspheres) were mixed with the CPC powder before 
liquid hardener (2% Na2HPO4) was added. In contrast, PTMC microspheres 
were first dispersed into the liquid hardener before mixing with CPC powder. 
Finally, all the resultant materials were mixed for 15 sec in a 2-mL syringe 
(Kendall monoject®, Gosport, UK) sealed with closed tip inside a mixing 
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apparatus (Silamat®, Vivadent, Schaan, Liechtenstein). After mixing, the tip was 
removed and cement composite was immediately injected into the femoral 
condyle defect. To compare the in vivo response and degradation for all composites, 
macroporosity (volume percentage of microspheres) was kept in the same range 
of 48-57 %. [16]
2.3   Morphology analysis and particle size determination  
of microspheres
PLGA, GEL and PTMC microspheres were assessed individually, and they were 
also assessed as embedded in fractured samples of hardened cement. Specimens 
were mounted on aluminum stubs using carbon tape, sputtered with gold, and 
visualized by scanning electron microscopy (SEM) (JEOL 6400-LINK AN 10000 
at 10 kV). The size distribution of the microspheres was determined via image 
analyses. The microspheres were suspended in demineralised water (ddH2O) 
and pictures were taken with an optical microscope (Leica DMRBE microscope, 
Leica Microsystems AG, Wetzlar, Germany), after which the size distribution 
was determined using digital imaging software (Leica Qwin, Leica Microsystems 
AG, Wetzlar, Germany). The number of counted microspheres was 268 for PLGA, 
222 for GEL and 246 for PTMC, respectively.
 
2.4  Porosity determination
The macro- and total porosity of the preset samples was determined according 
to a previous study [17]. The macroporosity is the porosity generated by the 
polymeric microspheres and relates to the volume of microspheres. The total 
porosity is the sum of the macroporosity and the microporosity of the cement. 
After the microspheres completely degrade, the macroporosity will equals to 
the volume% of microspheres present inside the cement initially.
Preceeding the measurement samples were dried overnight at 60°C. To determine 
the macroporosity and total porosity of a composite cement, samples with a 
known volume were placed in an oven at 650°C for 2 h. After burning out the 
polymer, samples were weighed and the equations 1 and 2 were used for the 
derivation of the total porosity and the macro-porosity:
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where mburnt is the mass of samples after burning (g), V is the volume of the 
sample (cm3), rHA is the density of hydroxyapatite (although the CPC is a mixture, 
this value is approximated by 3.156 g/cm3), mmacro is the average mass of the 
pure CPC cement sample after burning (g, n= 3), mmicro is the average mass of 
micro CPC (g, n= 3). Tests were performed in triplicate.
2.5 Animal model and implantation procedure
Eighteen healthy skeletally mature female New Zealand White rabbits, with a 
mass between 3.2 and 3.8 kg were used. The protocol was approved by the 
Animal Ethical Committee of the Radboud University Nijmegen Medical Centre 
(approval no: RU-DEC 2006-082) and national guidelines for the care and use of 
laboratory animals were observed. 
Surgery was performed under general inhalation anesthesia. The anesthesia 
was induced by an intravenous injection of Hypnorm (0.315mg/mL fentanyl 
citrate and 10 mg/mL fluanisone) and atropine, and maintained by a mixture of 
nitrous oxide, isoflurane and oxygen through a constant volume ventilator. To 
reduce the peri-operative infection risk, the rabbits received antibiotic 
prophylaxis (Baytril® ,2.5% (Enrofloxacin), 10mg/kg). 
The animals were immobilized on their back and the hindlimbs were shaved, 
washed and disinfected with povidone-iodine. After exposure of the distal 
femoral condyle a 2.0 mm pilot hole was drilled. The hole was gradually widened 
with drills of increasing size until a final defect of 4.2 mm in width and 6 mm 
in depth was reached. The whole process, low rotational drill speeds (max. 
450 rpm) and constant physiologic saline irrigation were used. After preparation, 
the defects were thoroughly irrigated and packed with sterile cotton gaze to 
stop bleeding. In this way, two defects were created in one femoral condyle 
(medial and lateral side), resulting in four femoral trabecular bone implant sites 
in each rabbit (i.e. totally 72 implant sites in eighteen rabbits)
All formulations of CPC/polymeric microspheres composites were injected in 
sequence according to a balanced split plot design, to ensure randomization. CPC 
cement without the addition of microspheres was included as control material. 
After injection, the superfluous cement was removed with a scalpel blade. After 
approximately 10 min to allow for setting of the cement, the soft tissues were 
closed layer-by-layer using resorbable Vicryl 4-0 sutures.
Implantation periods were 4, 8 and 12 weeks. At the end of each implantation 
time, the rabbits were sacrificed using overdose of Nembutal® (pentobartital) 
and the femoral condyles were retrieved for evaluation.
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2.6 Histological examination procedures 
The excess soft tissue of the retrieved femoral condyles was removed. Each 
condyle was split in a medial and lateral side, thus ensuring two specimens, 
which each contained one cement formulation. The specimens were subsequently 
fixed in 4% formaldehyde for 1 week, dehydrated in a graded series of ethanol 
and embedded (non-decalcified) in methylmethacrylate (MMA). Three thin (10 µm) 
non-decalcified sagittal cross sections of the cement were prepared using a 
sawing microtome technique. The sections were stained with methylene blue/
basic fuchsin and examined with a light microscope. The histological examinations 
included a descriptive observation, and quantitative evaluation adapted from 
our previous study[16], and was conducted by two evaluators according to an 
histological scoring guide (Table 1). Two evaluators scored individually. When 
the scores given the two evaluators for the same evaluated area differed more 
than 1 point, a discussion was held until a consensus was established. After each 
section was scored on four positions, scores were averaged per section, and the 
average score of 3 sections out of each sample was determined as the final score.
Table 1  Histological evaluation guide.
Tissue reaction in surface pores/ polymeric microspheres
Description score
Tissue in pores is mostly bone
Tissue in pores contains bone matrix deposition 
Tissue in pores is mostly cellular without remnants of polymeric components
Tissue in pores is cellular and remnants of polymeric components 
No porosity open for tissue ingrowth
4
3
2
1
0
Tissue response at the cement-bone interface
Description score
Direct bone contact without soft tissue interface
Remodeling lacuna with osteoblasts and/or osteoclasts at surface
Majority of implant is surrounded by fibrous tissue capsule
Unorganized fibrous tissue (majority of tissue is not arranged as a capsule)
Abundance of inflammatory cells and poorly organized tissue
4
3
2
1
0
Degradation of total scaffold
Description score
Complete replacement of scaffold by bone
Scaffold lost integrity, and is severely fragmented
Scaffold moderately decreased in size, integrity remained
Surface erosion of cement, minimal degradation of polymer microspheres
No obvious degradation of cement, polymer microspheres remained
4
3
2
1
0
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2.7 Statistical analysis
Statistical analysis was performed with GraphPad Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA) using one-way analysis of variance 
(ANOVA) with a Tukey multiple comparison test.
3. RESULTS
3.1   Morphologies of microspheres and CPC/polymeric microspheres 
composites and particle sizes of microspheres
The morphologies of the microspheres are shown in Figure 1. All three preparations 
showed well-preserved, rounded individual particles without aberrant shapes. 
In general, GEL particles showed a wider distribution in size compared to PLGA. 
PTMC spheres were markedly smaller in size. SEM microscopy of the set, and 
subsequently fractured, composite cements, showed a tight packing of the 
polymeric microspheres, with most of them being covered with a thin layer of 
calcium phosphate precipitate. The particle size of PLGA, GEL and PTMC micro- 
spheres were 33±17µm, 37±31µm, and 25±6µm, respectively. 
Sphere content and porosity characteristics of the composite cements are given 
in Table 2. To favor histological comparison, it was aimed to produce cements 
with approximating macroporosity, which meant that different sphere content 
was used for each formulation. [12,17,18] 
Figure 1   SEM images of the morphology of polymeric microspheres and the 
images of the CPC/PLGA, CPC/GEL and CPC/PTMC.
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3.2 Retrieved implants
During the study, one rabbit died as a result of a bacterial infection not related 
to the implantation. Hence, one sample of each formulation was lost. The other 
17 rabbits remained in good health and did not show any wound complication. 
At the end of the three implantation periods, a total of 68 implants were retrieved 
(6 rabbits x 4 implants after 4 weeks’ implantation; 5 rabbits x 4 implants after 
8 weeks’ implantation; and 6 rabbits x 4 implants after 12 weeks’ implantation). 
At retrieval, no visual signs of inflammatory or adverse tissue reactions were 
observed. 
3.3 Histological findings
3.3.1 CPC control
Representative histological findings are presented in Figure 2. CPC control samples 
revealed a dense structure overall, with air bubbles being only sporadically 
visible inside the implant due to the cement mixing and/or injection process. 
At the interface between bone and cement, no inflammatory cells or fibrous 
tissue were visible. At 4 weeks, the interface between the CPC and the surrounding 
tissues for the lager part consisted of a thin layer of newly formed bone. 
Sporadically osteoclast-like cells were visible inside disjunctive lacunas where 
CPC encountered bone marrow, indicating an active bone remodeling process. 
The amount of bone contact was the same for all implantation times. Between 
4 weeks and 8 weeks, the bone matured. Remodeling cellular activity was 
virtually quiescent at 12 weeks and seamless bone contact was established. In 
all sections, CPC resorption was limited to the peripherical area, and no further 
bone ingrowth was observed after 8 weeks (Figure 2).
3.3.2 CPC/PLGA microspheres composite 
Representative histological findings are presented in Figure 2. Similar to the 
case with the CPC control, direct bone contact to CPC matrix was observed at the 
interfacial area. At 4 weeks, many of the PLGA microspheres in the peripheral 
areas were already replaced with bone matrix or contained osteoclast-like cells. 
Table 2  Physical parameters of cement/microspheres formulations
Composite CPC/PLGA CPC/GEL CPC/PTMC
Average size microspheres (mm) 33 ± 17 37 ± 31 25 ± 6
Content of microspheres (wt%) 20 10 25
Microspheres (vol%) 48 57 49
Total porosity (%) 69 75 70
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At 8 weeks, multiple layers of microspheres were replaced by bone, and the 
original boundary of the implant was difficult to discern. However, the overall 
integrity of implant had remained. At the internal parts of the implant, the PLGA 
microspheres were mostly fragmented. At 12 weeks, all PLGA microspheres had 
disappeared and most of the pores were replaced by newly formed bone tissue 
(Figure 2). In 4 out of 6 samples, the scaffold had totally lost its integrity, and a 
normal cancellous bone structure was present. Profound interconnection 
between the spaces left by the PLGA microsphere was visible (Figure 3A).
Figure 2   Representative histological sections of the CPC and porous 
polymeric/CPC composites after 4, 8 and 12 weeks of implantation.
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3.3.3 CPC/GEL microspheres composite 
The histological findings are presented in Figure 2. At 4 weeks, sporadically 
degraded GEL microspheres were seen, which were replaced by new bone. 
However, inflammation was dominant, and, in 3 out of 6 samples, an abundant 
number of macrophages or multi-nucleated giant cells were present in intimate 
relation to the degrading GEL microspheres. At 8 weeks, a clear gap was visible 
between the surrounding bone tissue and the implant, in which lymphocytes 
were dominantly present in the central parts of the cement, and the GEL 
microspheres had remained intact. At 12 weeks, an abundant presence of 
lymphocytes was still visible at the interface. Intact GEL microspheres were no 
longer seen in the CPC matrix, and the bone contact had increased compared to 
8 weeks. Nevertheless, overall degradation of the implant remained limited. 
Limited interconnection of the porosity was observed (Figure 3B).
3.3.4 CPC/PTMC microspheres composite 
Representative histological findings are presented in Figure 2. At 4 weeks, the 
peripheral areas revealed a similar appearance to the PLGA cement. Degraded 
microspheres were replaced by bone, but smaller bone-like structures and less 
overall bone contact was observed. Many osteoclast-like cells were present. 
In contrast, after 8 and 12 weeks, no further bone ingrowth was visible. 
The morphology of the implants remained similar, and the internal PTMC 
microspheres remained intact. Interconnection of porosity was only found in 
the peripheral area (Figure 3C).
3.4 Quantitative evaluations 
3.4.1 Response to surface pores/polymeric microspheres 
Evaluation of the tissue behavior showed that the reaction toward the CPC/
PLGA microspheres composite cement significantly improved with observation 
time point (4-8weeks: p=0.004;8-12weeks: p=0.037) and consisted for the major 
part of bone at 12 weeks of implantation (Figure 4A). In contrast, there was no 
significant progression in tissue response to the CPC/GEL microspheres and 
CPC/PTMC microspheres composite cements (p>0.05) At 12 weeks the pores 
were mainly filled with fibrous tissue, inflammatory cells and polymeric 
remnants.
Comparison between the groups at individual time points, showed at 4 weeks, 
both CPC/PLGA and CPC/PTMC revealed significantly higher scores compared 
to CPC/GEL (p=0.005 and 0=0.016 respectively). At 8 and at 12 weeks, only CPC/
PLGA showed a significantly better response compared to other experimental 
groups (p=0.001), while no significant differences were found between the CPC/
GEL and CPC/PTMC groups (p>0.05). 
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3.4.2 Responses to the cement-bone interface
At the cement-bone interface, the extent of bone contact at interface increased 
over time in the CPC, CPC/PLGA and CPC/PTMC groups (Figure 4B). However, 
CPC/GEL revealed significant low score scale during all time periods, compared 
to all other groups (p=0.001). At 4 weeks, both CPC and CPC/PLGA showed 
significantly better response compared to CPC/PTMC (p=0.049 and 0=0.035 
Figure 3   Representative histogical sections of the polymeric/CPC composites 
after 8 weeks of implantation. A: Ingrowth of bone into degraded 
microspheres of CPC/ PLGA was visible. Note the profound inter-
connection of PLGA microspheres. B: Ingrowth of bone in the degraded 
PTMC microspheres of CPC/PTMC was only found at the peripherical 
area. C: Gap filled with lymphocytes between bone and CPC/GEL 
implant. Arrows indicate interconnection, OC=osteoclast, M=multi-
nucleated giant cell, L = lymphocytes.
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Figure 4   Histological scoring of samples after 4, 8 and 12 weeks of 
implantation. A: response to surface pores/polymeric microspheres, 
B: tTissue response at the interface and C: degradation of implant 
scaffold.
A
B
C
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respectively). After 8 and 12 weeks, no significant differences were found 
between the CPC, CPC/PLGA and CPC/PTMC groups (p>0.05).
3.4.3 Total degradation of scaffold 
Overall degradation was limited at all observation time points except for the 
CPC/PLGA (Figure 4C). This group showed significant degradation after 12 
weeks, compared to all other groups (p=0.001). Moreover, the degradation at 12 
weeks was significantly higher compared to that at 8 weeks(p=0.001). 
4. DISCUSSION
In this study, the in vivo bone tissue response towards three formulations of 
CPC/polymeric microspheres composites was investigated by means of histological 
examination. The study was aimed to determine the influence of different 
polymer microspheres on the degradation behavior of in-situ delivered CPC. 
Although a non-critical size defect model was used, this model still proved 
appropriate to illustrate parameters relevant for the degradation of the composites 
cements and the subsequent tissue response. As a positive control, the overall 
observations on solid CPC suggested that this matrix exhibited a favorable bone 
response, but was combined with an inferior resorption even at 12 weeks of 
observation. In general, the incorporation of degradable polymeric microspheres 
showed a positive effect on increasing the porosity of the composite cement. 
However, biological responses varied greatly. In the present study, only the CPC/
PLGA formulation resulted in the aimed accelerated resorption. 
To explain the results, first of all it seems that the geometric aspects of the 
porous implant played an important role in tissue ingrowth. Interconnection of 
the porosity is a requirement for bone ingrowth into CPC/polymeric micro - 
spheres composites. In all sections, the composite cement provided with PLGA 
microspheres showed extensive interconnectivity. This could particularly well 
be visualized at the 8 weeks sections, where microspheres had been replaced 
by bone and cluster-like structures clearly evidenced interconnection between 
the newly formed bone ingrowth. The other groups seldom showed similar 
morphological features.
Although in each formulation, an optimal mass ratio of matrix and microspheres 
for theoretic interconnection had been used, only the PLGA microsphere 
revealed the expected connection. On the other hand, it should be mentioned 
that using the same mass ratio to standardize the groups did not allow for fully 
equal morphology. The PLGA microspheres were larger in size than the PTMC 
ones, which, by itself, also increases the probability of interconnection between 
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microspheres. Possibly, if the mass ratio of PTMC had been increased accordingly, 
future applications can still be envisioned. It should also be noted, that the 
porosity data have to be regarded carefully. After calcining at 650°C, not only 
the polymer would be burned out, but the hydrated CPC would be also 
decomposed. In other words, the mass of a burned sample will deviate somewhat 
and thus is an approximation for determining the porosity, and marginal 
differences can occur. 
From a polymer chemistry point-of-view, break down can be characterized by 
erosion (i.e. mass loss) and degradation (i.e. shortening of the polymer chain 
length). However, in our study, the term, “degradation” is used to describe the 
breakdown of the entire polymer/cement composite. Still, the different mechanisms 
of breakdown of the individual polymer particles should be taken into account. 
The degradation rate of CPC/PLGA composite cement clearly displayed a known 
erosive pattern of the spheres. 8 weeks after implantation, a significant difference 
in degradation of the total scaffold was observed. It is well known that PLGA 
degrades by means of random hydrolysis. It has been reported that the 
degradation process is complete within approximately 8 weeks, depending on 
parameters such as porosity, molecular weight and dimension of the PLGA 
device[19-21]. The degradation behaviour will change from hetero -geneous to 
homogeneous when the dimensions of the polymer microspheres are becoming 
below 300 microns in diameter[22]. In the present study, PLGA with a molecular 
weight of 54.2kg/mol was used. In vitro, degradation of a CPC cement that 
contained such PLGA microspheres occurred rapidly [13-14]. Hence, we deduced 
that this in vivo finding corroborates such degradation of PLGA.
PLGA degrades into lactic and glycolic acids. Although both are harmless 
physiological metabolites, the protons released can cause a local increase in 
acidity, and thus potentially can cause inflammation or tissue necrosis if the 
capacity to clear degradation products at the site of the implant is not adequate. 
Therefore, the effect of degradation products must be considered before a CPC/
PLGA microspheres composite cement is used in clinical applications. As the 
effects of acidity, which is created by degradation of aliphatic polyesters, will 
depend on the size of the implant, the extent of decrease of pH is suggested to be 
mild in small microspheres compared to bulk application of PLGA material 
[23,24]. 
It can be assumed that the acid produced, when PLGA degrades, dissolves 
calcium phosphate to a certain extent, reaching neutralization. The resulting 
increase in the total concentration of calcium and phosphate ions could favor 
mineralization and new bone formation, and further improve interconnection 
between the pores as left by the microspheres. After mixing of the composite, 
technically the microspheres do not contact to each other. Even when a high 
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polymeric microspheres mass ratio is used, the microspheres are always 
separated by a thin layer of CPC matrix due to the fluidity of the CPC paste. The 
final deterioration of the hard inorganic “shell” around each individual 
microsphere, after the setting of CPC, finally leads to the interconnection. The 
hydrolysis process of PLGA thereby could well be an advantage since the 
accumulation of acidic end products can already partially or completely dissolve 
the “shell” structure. This assumption is confirmed by the enlarged pore 
morphology in the histological sections of the 8 weeks’ samples. More studies 
are needed to examine this issue. In contrast, gelatin and PTMC microspheres 
are broken down by a proteolysis mechanism. This enzyme-specific degradation 
leads to surface erosion[15]. The end-products of this process were reported to 
have a neutral pH value, which, in general, is considered an advantage in 
orthopaedic surgery[28]. This advantage, however, is not reflected in the present 
study, especially since the geometric aspect did not lead to interconnection. 
Apparently, the intrinsic microporosity of the CPC matrix does not allow for 
sufficient infusion of proteolytic enzymes. Furthermore, such degrading 
enzymes might exhibit great affinity for the CPC matrix. Therefore, degradation 
of cement with containing either gelatin or PTMC microspheres was observed 
only at the periphery, where, possibly, they encounter enzymatic activity. 
Subsequently, in these two composite cements, bone ingrowth was confined to 
the boundary areas. 
The inflammation as occurred at all implantation times when the CPC/GEL 
composite cement was used, was probably related to the source of the gelatin; 
namely, derived from pig. Although the immunogenic potency of this form of 
gelatin is low after synthetic hydrolyzation[25], cases of allergic reactions have 
been reported [26,27].
Thus, in future animal model studies involving CPC/gelatin microspheres 
composite cements, special attention should be paid to selection of the source of 
the gelatin. 
Finally, direct comparison with other studies from our group is impossible, as 
variations in experimental setup exist. For example, composite materials were 
implanted usually as preset discs, whereas the present model allowed an injectable 
application. Further, the site of implantation varies between all of these studies 
[10,13,16]. Nevertheless, CPC/PLGA microspheres composite cement showed 
most optimal biological behavior throughout all the experiments.
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5. CONCLUSION
For an injectable composite cement comprising CPC and microspheres of a 
polymer, resorption is dependent on both a geometric effect and the mechanism 
of degradation of the used microspheres. Dense cement without the inclusion of 
polymer spheres shows excellent bone contact, but no obvious degradation. The 
degradation properties of the CPC/PLGA microspheres composite and its bone 
response when implanted in the femoral condyles of rabbits were significantly 
better than those of CPC/gelatin and CPC/PTMC microspheres composites. The 
CPC/PLGA composite cement was found to be almost completely degraded and 
replaced with bone after 12 weeks.
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1.  INTRODUCTION
With an estimated, annual number of ~2.5 million procedures, bone grafting has 
become a substantial surgical intervention in medical and dental healthcare [1], 
Although autografts represent the primary choice for a grafting material, issues 
related to autograft availability and quality urge for alternatives.
From a practical point of view, the use of synthetic bone substitutes for bone 
regenerative treatments has several advantages over autografts, including off- 
the-shelf availability and minimal patient discomfort, as no additional surgery is 
necessary to harvest autologous bone. Additionally, the application of the bone 
substitute material should be simple and effective, meaning that material 
preparations within the operating theatre do not involve cumbersome steps and 
that the handling properties of the bone substitute material allow to perfectly 
fill the bone defect. In this respect, injectable bone substitute materials are 
appealing for reasons of their syringe-based application via minimally invasive 
surgery and their capacity to optimally fill irregularly-shaped defects [2;3].
In view of the composition of such synthetic bone substitutes, calcium phosphate 
(CaP) based ceramics are well-known for their superior biological performance 
in bone regenerative approaches [4]. In an injectable form, CaP cements (CPCs) 
were introduced by Brown and Chow in the early 1980’s [5]. Such CPCs are 
currently available with either brushite [6] or apatite [7] as the main end-product. 
Although brushite CPCs are readily degradable, their low mechanical properties 
limit their wide application. On the other hand, apatite CPCs have higher 
mechanical properties, but their slow degradation limits timely full
replacement by newly formed bone tissue.
Research efforts in the past decade have focused on enhancing the degradation 
of apatite CPC by introducing porosity within the ceramic matrix. Initial efforts 
utilized foaming agents (e.g. CO2) that induce the formation of gas bubbles within 
the CPC during setting [8]. For reasons of lack of control on pore size and pore 
distribution, the inclusion of rapidly degrading microspheres was explored. From 
multiple polymeric materials, poly(lactic-coglycolic acid) (PLGA) demonstrated to 
have most suitable properties regarding both control on degradation [9] as well 
as tissue response [10]. More specifically, the amount of PLGA microspheres 
[11], PLGA molecular weight and end-group functionalization demonstrated to 
have significant effects on the degradation of PLGA microspheres, leading to fast 
degradation and substantial bone formation for CPC formulations containing 
PLGA microspheres with a low molecular weight (~< 20kDa) and acid-terminated 
polymer chains [12;13].
To date, the effects of pore dimensions obtained after hydrolytic degradation of 
PLGA microspheres within CPC have not been addressed. Several discrepancies 
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exist with respect to adequate pore size of ceramic materials to allow bone 
ingrowth and substantial bone formation. A number of reports concluded 
that pore dimensions of at least 50 μm are required to allow cell ingrowth and 
blood vessel ingrowth to aid in scaffold degradation [14,15]. In contrast, other 
studies concluded that human osteoblasts can penetrate into interconnective 
porosity if the pores are over 20 micrometer in size [16] or even that pore size 
does not significantly affect tissue ingowth and resorption of calcium phosphate 
scaffolds [17].
In view of these controversial results, the aim of the current study was to 
elucidate the true effect of the pore dimensions within CPC on bone formation 
after injection of CPC/PLGA in a guinea pig tibial intramedullary model. To this 
end, injectable CPC/PLGA formulations were prepared using PLGA microspheres 
with either a small (~25 μm) or large (~100 μm) diameter, which were incorporated 
at a 20/80 ratio (wt.%) within apatite CPC. Both CPC/PLGA formulations were 
injected into a marrow-ablated tibial intramedullary cavity and after an 
implantation period of 12 weeks, histology and histomorphometry were used 
to address bone formation.
2. MATERIALS AND METHODS
2.1. Materials
The chemical composition of the cement consisted of commercially available 
calcium phosphate powders: 85% (wt/wt) alpha-tricalcium phosphate (a-TCP; 
CAM Implants BV, Leiden, The Netherlands), 10% (wt/wt) dicalcium phosphate 
anhydrous (DCPA; J.T. Baker Chemical Co., Phillipsburg, USA) and 5% (wt/wt) 
precipitated hydroxyapatite (pHA; Merck, Darmstadt, Germany). An aqueous 
solution of 2% Na2HPO4 (Merck, Darmstadt, Germany) was used as the liquid 
component. Poly(lactic-co-glycolic acid) (PLGA; Purasorb® PDLG 5002A 
(MW=17kDa, acid-terminated, L:G=50:50) was provided by Purac Biomaterials 
(Gorinchem, the Netherlands). For the preparation of the PLGA microspheres, 
polyvinyl alcohol (PVA; 88% hydrolyzed, Mw=22.000, Acros, Geel, Belgium), 
isopropanol (IPN; analytic grade, MERCK, Darmstad, Germany) and dichloro-
methane (DCM; analytic grade, MERCK) were used.
2.2. Preparation of PLGA microspheres
PLGA microspheres were prepared using a water/oil/water (w/o/w) double 
emulsion solvent evaporation technique. A total of 1.0 g of PLGA was dissolved in 
4 ml of DCM in a 20 ml glass tube, 0.5 ml of milliQ water was added and the 
emulsion was emulsified (small diameter microspheres: 8000 rpm for 90 seconds; 
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large diameter microspheres: 3200 rpm for 90 seconds) with an emulsifier 
(IKA® T25 digital ultra-Turrax®, IKA® Werke GMBH & Co. KG, Germany). 
Subsequently, 6 ml of a 0.3% PVA solution was added and emulsified again at 
8000 rpm for another 90 s. The content of the 50 ml tube was transferred to a 
stirred 1000 ml beaker containing 394 ml of 0.3% PVA. Following addition of 
400 ml of a 2% IPN solution, the suspension was stirred for 1 hour. After the 
microspheres were allowed to settle for 15 minutes, the suspension was 
centrifuged and the supernatant solution was decanted.
This washing procedure was repeated twice and the microspheres were 
collected, lyophilized for 24 hour and stored at -20°C.
2.3. Characterization of PLGA microspheres
The morphology and size distribution of the PLGA microspheres was determined 
by light microscopy. Microspheres were suspended in H2O and images were 
acquired using an optical microscope equipped with a digital camera (Leica/
Leitz DM RBE Microscope system, Leica Microsystems AG, Wetzlar, Germany). 
Thereafter, digital image software (Leica Qwin®, Leica Microsystems AG, 
Wetzlar, Germany) was used to determine microsphere size distribution using a 
sample size of >300 microspheres. In addition, microsphere morphology was 
assessed using scanning electron microscopy (SEM, JEOL 6310) at an accelerating 
voltage of 10 kV, which was performed at the microscope imaging centre (MIC) 
of the Nijmegen Centre for Molecular Life Sciences (NCMLS).
2.4. Preparation of CPC/PLGA formulations
CPC/PLGA formulations were generated by adding 0.2 g PLGA microspheres to 
0.8 g CPC powder inside a 2-ml plastic syringe. The two different CPC/PLGA 
formulations as such created contained either small microspheres (CPC/PLGA-S) 
or large microspheres (CPC/PLGA-L). All syringes were sealed with a closed tip 
and sterilized using gamma radiation (25-50 kGy; Isotron BV, Ede, the 
Netherlands).
2.5. Characterization of CPC/PLGA composites
The physico-chemical characterization of the CPC/PLGA formulations was 
conducted as described previously [9;13]. Briefly, the porosity of these 
formulations was assessed by preparing pre-set, cylinder-shape scaffolds (n=3) 
using Teflon molds, after which the diameter, height, and weight of these 
scaffolds were measured before and after heating the scaffolds at 650°C for 2 
hours. The total porosity and the macro-porosity were derived by the equations 
described previously [18].
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2.6. Animal model and implantation procedure
Twenty guinea pigs (age: 7 months; gender: female; Harlan, Horst, the Netherlands) 
were used as experimental animals, which each received uni-lateral surgery of 
only the right tibia. The study was approved by the Animal Ethics Committee 
of Nijmegen, the Netherlands (DEC 2009-127) and national guidelines for the 
care and use of laboratory animals were respected. General anesthesia was 
maintained by 0.5-2% Isoflurane, administered through inhalation and the 
depth of anesthesia was monitored by a lack of response to toe pinch and by 
monitoring the depth of respiration. To reduce peri-operative infection risk and 
minimize post-operative discomfort, antibiotic prophylaxis (Baytril®, 2.5%; 
Enrofloxacin, 10 mg/kg) was administered prior to surgery and daily from day 
1-3 post-surgery.
For injection of the CPC/PLGA formulations, the animal was immobilized on its 
back and the right hindlimb was shaved, washed and disinfected with povidone- 
iodine. Two small longitudinal incisions were made along the distal and proximal 
tibial diaphysis. After exposure of the tibia, a full-thickness cortical defect (2.0 mm 
in diameter) was made in both distal and proximal sites using low rational drill 
speeds (max. 450 rpm) and constant saline irrigation. The content of the marrow 
space was evacuated by curettage using a dental file and repeated irrigation 
with saline; a sterile cotton gauze was applied to stop bleeding. Then, the CPC/
PLGA formulation was prepared within the operating theatre by adding 0.38 ml 
of sterile 2% Na2HPO4 solution to a syringe containing either CPC/PLGA-S or 
CPC/PLGA-L and mixed vigorously for 30 seconds (Silamat® mixing apparatus, 
Vivadent, Schaan, Liechtenstein). After removing the tip of the syringe, the CPC/
PLGA formulation was immediately injected into the bone marrow ablated tibia 
medullar cavity. The distal hole served as entrance and the proximal one as 
evacuation site for CPC/PLGA (Figure 1a).
After injection, the CPC/PLGA formulation was allowed to set for 10 minutes, 
after which the excess material was removed with a spatula. Subsequently, the 
soft tissues were closed in two layers using resorbable sutures (monocryl 4-0). 
After surgery, animals were housed in groups and given water and chow ad 
libitum. Animals were physically examined on a daily basis during the first 10 
days post-surgery with focus on body weight, infection and adverse reactions. 
At 12 weeks post-implantation, animals were euthanized by an injection of 
concentrated sodium pentobarbital.
2.7. Histological and histomorphometrical evaluation
Immediately after euthanasia, the tibias were retrieved and fixed in 4% 
formaldehyde for 1 week and dehydrated in a graded series of alcohol. After 
dehydration, tibias were cut into two parts: a proximal and a distal part. These 
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parts were alternately allocated to two groups: the first group was composed of 
proximal halves of even tibias and distal halves of odd tibias, the second group 
was composed of distal halves of even and proximal halves of odd tibias. The 
first group was left non-decalcified, and embedded in poly methyl methacrylate 
(PMMA). After polymerization, these blocks were used to prepare thin (10 μm) 
sections (n=3 for each half tibia) using a Leica SP1600 saw microtome. These 
sections were made perpendicular to the long axis of the tibia and stained with 
methylene blue/basic fuchsin. The second group of specimens was decalcified 
with a specific-purpose apparatus (TDE30, Sakura) and dehydrated in a graded 
series of ethanol. Finally, the specimens were embedded in paraffin and 
histological sections were prepared using a standard microtome (RM 2165, 
Leica) in three different regions of the tibia (Figure 1b): close to the distal entry 
site, in the central part of the diaphysis, and close to the proximal exit site. For 
each region, a total of six sections were stained with hematoxylin and eosin (HE) 
and another six sections were stained with Elastica van Gieson (EVG). 
Histological evaluation was done using an optical microscope (Axio Imager 
Microscope Z1, Carl Zeiss Micro imaging GmbH, Göttingen, Germany) and 
consisted of a concise description of the observed specimens. Histomorphomet-
rical evaluation was performed using EVG-stained paraffin sections in order to 
have the highest resolution for detecting bone formation inside the medullar 
cavity. For quantification, 3 sections of each region per tibia (Figure 1b) were 
used. Two regions of interest (ROI) were set: ROI-1 was set to demarcate the 
intramedullary cavity, ROI-2 was determined based on morphological and color 
discrimination between tissue and ceramic matrix within ROI-1 (Figure 1c). The 
bone area within both these ROIs was measured using Leica Qwin software 
(Leica Microsystems Imaging Solution, Cambridge, UK).
2.8. Statistical analysis
Statistical analysis were performed using GraphPad Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA). The statistical comparison 
between the two CPC/PLGA formulations was performed using an unpaired 
Student’s t-test. Alternatively, a one-way ANOVA was used to analyze bone 
formation at different regions. Differences were considered significant using at 
P-values <0.05.
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3. RESULTS
3.1.  Characterization of PLGA microspheres and CPC/PLGA 
composites.
SEM micrographs of the prepared PLGA microspheres and obtained CPC/PLGA 
composites are depicted in Figure 1.
Both small and large PLGA microspheres showed a spherical morphology. 
The size distribution measurements revealed an average microsphere diameter 
of 27±7 μm for small and 100±35 μm for large PLGA microspheres (p<0.05).
When incorporated within CPC, the morphology of pre-set CPC/PLGA scaffolds 
showed a tight packing of the PLGA microspheres. Furthermore, the PLGA 
microspheres were distributed homogeneously throughout the CPC-matrix. 
An apparent increase in interconnection of PLGA microspheres was observed 
for CPC/PLGA-S compared to CPC/PLGA-L (Figure 2b,d). The total porosity of 
CPC/PLGA-S and CPC/PLGA-L was similar with values of. 67.2±1.5% and 
66.9±0.6%, respectively, (p>0.05), to which the PLGA microspheres contribute 
in the form of macroporosity of ~45% (Table 1).
Figure 1   (A) Injection of CPC/PLGA into the bone marrow ablated tibia medullar 
cavity where the distal hole served as entrance and the proximal  
one as evacuation site. (B) Three different regions of the tibia defined 
for histological analysis; P and D indicates proximally and distally 
drilled hole, respectively. (C) Regions of interest (ROI): ROI-1 
demarcates the intramedullary cavity and ROI-2 refers to the CPC-PLGA 
area within ROI-1.
A B C
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3.2. Clinical observations.
The surgical procedure was uneventful for all animals. In the course of the 
implantation period, 3 animals (2 CPC/PLGA-L and 1 CPC/PLGA-S) were sacrificed 
due to a tibial fracture. The other 17 animals remained in good health and did 
not show any wound complications (i.e. signs of inflammation, such as swelling 
and redness). After the 12-week implantation period, a total of 17 tibias with 
Figure 2   SEM micrographs of (A) large, (B) small PLGA microspheres, (C) CPC/
PLGA-L and (D) CPC/PLGA-S.
Table 1  Characteristics of PLGA microspheres and CPC/PLGA formulations.
Name PLGA/CPC-S PLGA/CPC-L
Average size microspheres (mm) 27 ±7 100 ± 35
Wt % microspheres 20 20
Porosity (%) 67.2 ± 1.5 66.9 ± 0.6
Macroporosity (%) 44.5 ± 2.5 44.1 ± 1.0
Processed on: 10-4-2017
509124-L-bw-Liao
88
injected CPC/PLGA formulations (i.e. 9 CPC/PLGA-S and 8 CPC/PLGA-S) were 
retrieved. An overview of the number of implants placed and retrieved is given 
in Table 2.
3.3. Histology and histomorphometry
3.3.1.Descriptive histology
PMMA-sections (Figure 3) demonstrated presence of CPC/PLGA within the 
intramedullary cavity (dark areas) at the distal side with full contact with the 
Figure 3   Representative histological images of PMMA sections of the  
(A) proximal, (B) central and (C) distal regions of the tibia containing 
CPC/PLGA-L composites. The voids between the CPC/PLGA and 
cortical bone in the proximal region are indicated with asterisks (*).
Table 2  Experimental groups, number of implants placed and retrieved.
Experimental 
group
Composition Implants 
placed
Implants 
retrieved
CPC/PLGA-L CPC with 20 wt.% large 
PLGA microspheres
10 8*
CPC/PLGA-S CPC with 20 wt.% small 
PLGA microspheres
10 9*
* Deviation from # implants placed due to fracture of the tibia during implantation period.
C
A B
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cortical bone. In contrast, the proximal side showed less contact between CPC/
PLGA and cortical bone, leaving voids.
These voids were partially filled with newly-formed bone (Figure 3C). Since 
PMMA sections did not allow accurate discrimination between CPC and tissue, 
paraffin-sections of decalcified specimens were used. EVG-stained sections 
clearly showed abundant bone formation within the intramedullary cavity 
(Figure 4). More specifically, H&E-stained sections (Figure 5) allowed identification 
of the CPC-matrix and showed two distinct morphologies with trabecular-like 
bone structures in the areas outside CPC-matrix (either not present or 47 degraded) 
and round bone structures inside the CPC-matrix (Figure 5). For CPC/PLGA-L, 
these round bone structures showed embedded osteocytes within the bone 
matrix and had dimensions ~100 μm in diameter, in which frequently cavities with 
marrow-like tissue was observed. For CPC/PLGA-S, much smaller dimensions 
Figure 4   Representative EVG-stained sections of (A) CPC/PLGA-L and (B) CPC/
PLGA-S. Black arrows indicate interconnected pores filled with  
bone and white arrows point at pores filled with bone that maintain 
the original size and morphology of PLGA microspheres.
A
B
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Figure 5   Representative HE histological sections of the proximal region with 
(A) CPC/PLGA-L and (B) CPC/PLGA-S. Lower panels are magnifications  
of the indicated boxes in the image above. Yellow and black asterisks 
indicate the presence of marrow-like tissue and trabecular-like bone 
structures containing osteocytes, respectively. Black arrows point  
at remnants of CPC.
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for these round bone structures were observed (~20 μm), which frequently had 
fused into trabecular-like bone structures. Marrowlike tissue was observed 
between these larger trabecular-like bone structures inside the CPC-matrix. 
The newly-formed bone showed always (also, in the round boen structures) the 
presence of osteocytes.
3.3.2. Histomophometrical evaluation.
Bone formation was evaluated within 2 different ROIs, which covered either the 
entire intramedullary cavity or the area of the CPC-matrix (Figure 1c). The 
results on bone formation are depicted in Figure 6.
Total bone formation within ROI-1 (= average of measurements at different 
regions, i.e. distal, central and proximal; Figure 6A) for CPC/PLGA-S and CPC/
PLGA-L was 26.9±19.2% and 24.4±18.7, respectively (p>0.05). Total bone 
formation measurements within ROI-2 (= average of measurements at different 
regions, i.e. distal, central and proximal; Figure 6A) revealed that CPC/PLGA-S 
showed significantly higher amounts of bone (23.8±15.6%) compared to CPC/
PLGA-L (9.9±7.9; p=0.0093). (Figure 6A).
For different regions of the tibial intramedullary cavity (i.e. distal, central and 
proximal), both CPC/PLGA formulations demonstrated similar amounts of bone 
within ROI-1 (p>0.05; Figure 6B), whereas region- and CPC/PLGA formula-
tion-related differences were observed within ROI-2 (Figure 6C). Region-related 
specification showed for both CPC/PLGA-formulations significantly lower bone 
formation in the central region compared to both the distal and proximal regions 
(p<0.05). Alternatively, formulation-related specification showed significantly 
higher bone formation for CPC/PLGA-S compared to CPC/PLGA-L in both the 
proximal and distal regions (p<0.05), but not in the central region (p>0.05).
4. DISCUSSION
The aim of the present study was to evaluate the effect of PLGA microsphere 
dimension on bone formation after injection of CPC/PLGA in a guinea pig tibial 
intramedullary model. The reported results reveal evidently that bone tissue 
can grow into porosity within CPC as created by the degradation of PLGA 
microspheres with dimensions as small as ~25 μm.
Importantly, total bone formation within the CPC/PLGA bone substitute 
demonstrated >2-fold bone formation for CPC containing small PLGA micro- 
spheres compared to CPC containing large PLGA microspheres. Additionally, the 
pattern of bone and marrow formation showed distinct differences depending 
on the dimensions of the PLGA-microspheres within the CPC-PLGA formulations.
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Figure 6   Quantification of bone formation. (A) Total bone formation in ROI-1  
(= average of all different levels at which sections were made (distal, 
central, proximal) and total bone formation in ROI-2 (= average of  
all the different levels at which sections were made (distal, central, 
proximal). (B) Bone formation in ROI-1 at the different levels.  
(C) Bone formation in ROI-2 at the different levels.
A
B
C
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Compared to other small animal models used for the pre-clinical evaluation of 
bone substitute performance (e.g. murine calvaria and femoral epiphysis) 
[19,20], the presently used model comprises several differences. Firstly, an 
intramedullary cavity is not a bony site in the sense that the native tissue in that 
area consists of bone. As such, it cannot be considered as a bone defect, but 
rather as a bone augmentation model, in which native bone tissue is activated 
from the endosteal site following bone marrow ablation [21,22]. Secondly, the 
tissue surrounding the site of injection is different from that in normal bone 
defect and bone augmentation models. Whereas in these latter models, the site 
is surrounded by either bone tissue or soft tissue, the intramedullary cavity is 
composed of bone marrow and fat tissue, while being circumferentially 
surrounded by cortical bone. Despite this difference with regular bone defect 
and bone augmentation models, the guinea pig tibial intramedullary model was 
chosen because it allows that the cement can indeed be tested as an injectable 
material and also provides large-sized histological specimens, which can be 
subjected to multiple approaches for analysis (i.e. both embedding in PMMA and 
paraffin of alternate tibial halves).
Regarding the quantification of CPC/PLGA degradation, the intramedullary 
model has several limitations. For a reliable assessment, it is mandatory to 
achieve complete filling and setting of the injectable CPC/PLGA bone substitute. 
Within a secluded cavity connected to liquid areas (i.e. bone marrow) proximally 
and distally, it remains speculative if that can be achieved. It needs to be 
emphasized that for regular bone defect models, the defect is maximally dried to 
avoid interference of bodily fluids with filling and setting [23;24].
Examination of the PMMA sections revealed that both CPC/PLGA formulations 
were still present within the intramedullary cavity at the end of the 12 weeks 
implantation time. Due to the high density of the CPC/PLGA composite material, 
the relative thickness of PMMA sections and artifacts caused by staining, 
analysis of bone formation using PMMA embedding is inaccurate [25]. In 
contrast, HE and EVG staining of de-calcified paraffin sections indicated the 
presence of abundant bone formation within the CPC-matrix. As such, these 
results demonstrate the importance of combined analysis (calcified/de-calcified) 
for a complete understating of both processes (material degradation and bone 
formation.
The quantitative assessment of bone formation showed no differences in total 
bone formation within the tibial intramedullary cavity related to PLGA 
microsphere dimension.
However, within the CPC-matrix, bone formation of CPC/PLGA with small PLGA
microspheres was >2-fold higher compared to CPC/PLGA with large PLGA 
microspheres.
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Further specification of this difference showed that especially the proximal and 
distal regions 49 of the tibial intramedullary cavity contributed to this result. 
This effect is likely to be caused by bone marrow as left at the proximal and 
distal ends of the intramedullary cavity after the ablation procedure. This 
remained bone marrow could have acted as an initiator for new bone formation.
Review of previously performed studies indicate that no conclusive statement 
can be made about the scaffold requirements (porosity, composition, etc.) to 
allow bone ingrowth. For example, in vivo studies with ectopic implantation of 
pre-set CPC/PLGA scaffolds have shown that soft tissue ingrowth throughout 
the scaffold is feasible with PLGA microsphere sizes >50 μm incorporated at 20 
wt.% [15]. Alternatively, the assessment of bone ingrowth into biomaterials 
with different compositions (i.e. sintered hydroxyapatite with ‘cellular’ or 
‘strut-like’ design) and porosity characteristics (i.e. porosity 32-56%, pore 
radius 71-167 μm) showed that pore size was strongly correlated to bone 
ingrowth with a strong enhancement of bone ingrowth when pore diameters 
exceed 100 μm [26]. Also one of our recent studies indicated that a CPC/PLGA 
formulation with 30 wt.% PLGA microspheres of 40 μm would be optimal 
regarding mechanical properties, porosity, and interconnectivity [11]. This 
inconsistency in observations is confirmed by the present study, which shows 
that bone ingrowth throughout the material was obtained for an injectable CPC/
PLGA formulation with 20 wt.% PLGA microspheres of ~25 μm. This formulation 
showed even significantly more bone formation compared to the CPC/PLGA 
formulation with 20 wt.% PLGA microspheres of ~100 μm, while formulations 
had a similar total porosity (~67%) to which the PLGA equally contributed (i.e. 
macroporosity of ~44%). In contrast with previous studies, which reported that 
small pore sizes (40-80 μm) lead to less bone formation than larger pore sizes 
(200-400 μm) [27,28], it seems straightforward to conclude that a higher pore 
interconnectivity of the CPC/PLGA-S material caused the currently observed 
favorable effect on bone ingrowth. However, it has to be emphasized that in 
addition to the created macroporosity due to PLGA degradation, CPC/PLGA 
possesses an intrinsic nanoporosity. Therefore, the majority of CPC/PLGA pores 
are additionally interconnected via this nanoporosity, which allows for enhanced 
fluid flow and nutrient circulation within the material. At the same time, the 
fluid flow circulation can accelerate the transformation as well as degradation 
of the CPC resulting in more space for tissue ingrowth.
Within the tibial intramedullary cavity. the response to several ceramic bone 
substitutes has previously been described to follow a pattern from endosteal 
bone healing via marrow cavity remodeling to marrow restoration [29]. The 
results of the present study not only show an effect of remaining bone marrow 
on bone formation, but also demonstrate that marrow regeneration occurred 
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within the CPC-matrix. Interestingly, the location of regenerated bone marrow 
was dependent on the size of the PLGA microparticles: whereas large PLGA 50 
microspheres evoked bone formation in round patterns and marrow in the 
center, small PLGA microparticles appeared to give rise to trabecular-like bone 
formation with bone marrow present between such trabeculae. As described in 
the literature, anatomical restrictions necessitate specific dimensions (i.e. 
porosity) to allow bone marrow and blood vessel formation [30,31]. However, 
this study provides sufficient evidence that new bone formation occurs 
throughout a CPC-matrix with pores of 25 μm in diameter. Therefore, it can be 
hypothesized that CPC nanoporosity, in combination with the porosity generated 
after PLGA degradation, provides sufficient space for nutrient diffusion to allow 
bone cells to survive with the presence of bone marrow, but without the 
formation of new blood vessels until further degradation of the CPC-matrix. This 
observation closely resembles the situation that occurs in nature within the 
cortical bone structures, where the Haversian system contains blood vessels 
only in the Volkmann’s canal. Nutrients diffused out from the vessel within these 
canals to the osteocytes in the Haversian system via nano-sized canaliculi.
5. CONCLUSION
The results of the present study demonstrate that the dimension of PLGA 
microspheres within injectable CPC/PLGA have a substantial effect on bone 
formation. Whereas both small (~25 μm) and large (~100 μm) microspheres 
allowed bone ingrowth throughout the CPC-matrix, a >2-fold higher amount of 
newly formed bone was observed for CPC/PLGA with small PLGA microspheres 
within the CPC-matrix. Additionally, the pattern of bone and marrow formation 
showed distinct differences related to PLGA microsphere size. In general, this 
study demonstrates that PLGA microsphere dimensions of ~25 μm, leading to 
pores of ~25 μm within CPC, are sufficient for bone ingrowth and allow 
substantial bone formation.
Further, the results demonstrate that PLGA microsphere dimensions provide a 
tool to control bone formation for injectable CPC/PLGA bone substitutes.
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1.  INTRODUCTION
Calcium phosphate cements (CPCs) are frequently applied for bone regenerative 
treatments in oral, maxillofacial, cranial and orthopedic surgery due to their 
excellent bone response.1-3 Injectable CPCs offer several advantages over 
pre-shaped granules and blocks, since they can be i) applied using minimally 
invasive surgery, ii) easily molded to fill irregularly shaped defects, and iii) 
hardened within a short time into a solid and dense calcium phosphate mass. 
As such, CPCs are not associated with many of the drawbacks of auto- and 
allografts in terms of surgical harvesting, donor site morbidity and the risk of 
disease transfer.4 Based on the end-product of their setting reaction, CPCs are 
categorized as either brushite- or apatite-forming CPCs.5 Apatite-forming CPCs 
are generally preferred to brushite CPCs due to their superior mechanical 
properties and closer similarity to the mineral phase of bone and teeth. Apatitic 
CPCs are formed by either acid-base reactions between calcium phosphate 
precursor phases (e.g. basic tetracalcium phosphate and acidic dicalcium 
phosphate dihydrate) or hydrolysis of calcium phosphate phases such as 
α-tricalcium phosphate (α-TCP). Nevertheless, the cohesion of apatitic CPCs 
remains a clinical challenge in highly perfused bone defects, while widespread 
applicability of apatitic CPCs is compromised by their poor degradability.6-8 
Herein, we have used carboxyl methylcellulose (CMC) as a cohesion promotor. 
CMC is s polysaccharide commonly used for applications in cosmetics, food and 
pharmacy due to its non-toxicity and biocompatibility.9 In addition, it was shown 
previously that CMC was able to bond to calcium phosphate particles through 
the interaction between calcium ions and carboxyl side groups, thereby 
improving the clinical handling properties such as the injectability and cohesion 
of the cement.10,11
After setting in situ, the hardened CPCs lack porosity that allows for vascular-
ization and ingrowth of bony tissue.12.Poly(D,L-lactic-co-glycolic) acid (PLGA) 
microparticles have been used as porogens to provide sufficient porosity for 
tissue ingrowth and to accelerate the degradation of CPC. Previous studies 
confirmed that the incorporation of PLGA microparticles indeed stimulated 
the formation of porosity, while the acidic degradation by-products of PLGA 
(i.e. lactic and glycolic acid) have shown to be responsible for accelerated 
dissolution of the apatitic CPC matrix without compromising the safety and 
 biocompatibility of the CPC.13 By fine-tuning the degradability of the PLGA 
microparticles through variation of parameters such as molecular weight, 
end-group functionalization as well as the morphological characteristics of PLGA, 
Lanao et al. observed that 70% of the original CPC was degraded after 12 weeks 
of implantation in femoral condyles of rabbits. However, complete degradation 
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of the CPC was not observed within this implantation period.14 Therefore, we 
evaluated the osteocompatibility and long-term degradation behavior of both 
PLGA-containing and PLGA-free, α-TCP-based CPCs for implantation periods up 
to 26 weeks using an established rabbit femoral condyle model that was used in 
previous degradation studies. For reasons of comparison, the commercially 
available apatitic CPC bone substitute HydroSet™ was included as control group. 
CPC degradation and new bone formation were evaluated histologically and 
histomorphometrically after 4, 12 and 26 weeks of implantation.
2. MATERIALS AND METHODS
2.1 Materials
Poly(D,L-lactic-co-glycolic acid (PLGA) (lactic:glycolic acid ratio of 50:50, 
molecular weight of 17 kDa, acid-terminated) marketed as Purasorb PDLG 
5002A (Corbion Purac, Gorinchem, the Netherlands) was provided in the form of 
microparticles (volume mean particle diameter of 50 µm) by CAM Bioceramics 
(Leiden, The Netherlands). Blanose pharmacological grade sodium carboxyl 
methylcellulose (CMC) was obtained from Barentz Raw Materials ( Hoofddorp, 
the Netherlands) and sieved to remove any particles bigger than 106 µm, washed 
with 100% isopropanol (analytical grade, Merck, Darmstadt, Germany) to 
remove potential microbiological contamination and dried at 90°C overnight. 
Alpha-tricalcium phosphate (α-TCP) was provided by CAM Bioceramics BV 
(Leiden, The Netherlands). HydroSet™ Injectable HA Bone Substitute consisting 
of tetracalcium phosphate, dicalcium phosphate dihydrate and trisodium citrate 
in the powder phase and a liquid solution of sodium phosphate and polyvin-
ylpyrrolidone in water was purchased from Stryker (lot # IC06276A, Stryker®, 
Stryker International, Limerick, Ireland).
2.2 CPC formulation
Two experimental apatite-forming CPC formulations were prepared. Briefly, to 
prepare the PLGA-free CPC-CMC formulation, 0.015 g of CMC was mixed with 
0.985 g of α-TCP and 0.5 ml of a 4 w/v % aqueous solution of sodium dihydrogen 
phosphate dihydrate (NaH2PO4•2 H2O) at a liquid-to-powder ratio of 0.5 ml/g. 
Similarly, 0.015 g of CMC, 0.394 g of PLGA microparticles and 0.591 g of α-TCP 
were mixed with 0.52 ml of a 4 w/v % aqueous solution of NaH2PO4•2H2O to 
form a PLGA-containing CPC-CMC-PLGA composite. Each CPC was manually 
mixed and the paste was transferred to a Terumo ® syringe (Terumo Europe 
N.V., Leuven, Belgium and injected in a retrograde manner into the defects. 
HydroSet™ was applied in a similar way.
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The initial and final setting time of the experimental CPCs were assessed using 
Gillmore needles. A bronze block was used as mold containing 6 holes (6 mm in 
diameter, 12 mm in height). The mold was placed in a water bath at body 
temperature (37°C). The initial and final setting times of HydroSet™ were 
obtained from the manufacturer’s product data sheet.
2.3 Animal model and implantation procedure
36 skeletally mature female New Zealand White rabbits with a body weight 
between 3.2 and 3.6 kg were used as experimental animals. The protocol was 
approved by the Animal Ethical Committee of Guangxi Medical University 
(Approval no. 2013091201) and national guidelines for the care and use of 
laboratory animals were followed.
Surgeries were performed under general inhalation anesthesia. To reduce the 
peri-operative infection risk, the rabbits received intramuscular injection of 
penicillin as antibiotic prophylaxis. The animals were immobilized on their back 
and the hind limbs were shaved, washed and disinfected with povidone-iodine. 
After exposure of the distal femoral condyle, a 1.0 mm pilot hole was drilled. The 
hole was gradually widened with drills of increasing size until a final defect size 
of 4.85 mm in width and 6 mm in depth was reached (Figure 1). Low rotational 
drill speeds (max. 450 rpm) and constant physiologic saline irrigation were used 
to minimize damage to bone tissue. After preparation, the defects were 
thoroughly irrigated and packed with sterile cotton gaze to stop bleeding. 
Surgery was performed in both legs of the rabbits and one defect was created in 
each condyle. The mixing procedure was initiated after the femoral defect was 
surgically created. After mixing, the three different CPCs were injected into the 
circular condylar defects in a randomized manner (Table 1, n=8). After injection, 
the superfluous CPC was removed with a scalpel blade and soft tissues were 
closed layer-by-layer using resorbable Vicryl sutures after approximately 10 
minutes of setting. After 4, 12 and 26 weeks of implantation, rabbits were 
euthanized using an overdose of Nembutal® and the femoral condyles were 
harvested for evaluation.
2.4 Histological procedures
After harvesting the femoral condyles and removal of the surrounding soft 
tissues, the condyles were prepared for embedding in either polymethylmetha-
crylate (PMMA) or paraffin. For embedding in PMMA, the tissue blocks were left 
non-decalcified, fixed in 4% formaldehyde for 2 days, dehydrated in a graded 
series of ethanol and embedded in PMMA. After polymerization, at least three 
10 µm sagittal cross sections of the condylar part containing the composite 
implants were prepared on three pre-defined levels along the depth of the defect 
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using a sawing microtome technique. Sections were stained with methylene 
blue/basic fuchsin and examined with a light microscope (Leica Microsystems 
AG, Wetzlar, Germany). For paraffin embedding, the specimens were fixed in 
4% formaldehyde for 48 hours, decalcified in an ethylenediaminetetraacetic 
acid (EDTA) solution (10%), dehydrated through a graded series of ethanol 
(70%-100%), cut in half and finally embedded in paraffin. By using a microtome 
(Leica RM 2165, Leica Microsystems, Nussloch, Germany), a total of six 
histological (6 µm in thickness each) sections were prepared. Paraffin sections 
were stained with hematoxylin and eosin (H&E) to stain nuclei of cells, Elastic 
Figure 1   Photograph of femoral condyle after cement injection (A). Schematic 
of the implant location (B).
A B
Table 1  
Left Right
Rabbit 1 A B
Rabbit 2 C A
Rabbit 3 B C
Rabbit 4 A B
Rabbit 5 C A
Rabbit 6 B C
Rabbit 7 A B
Rabbit 8 C A
Rabbit 9 B C
Rabbit 10 A B
Rabbit 11 C A
Rabbit 12 B C
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van Gieson (EVG) to stain elastic fibers and Tartrate-Resistant Acid Phosphatase 
(TRAP) to stain osteoclasts in the sections.
2.5 Histomorphometrical analysis
In addition to a qualitative histological description, a quantitative histomorpho-
metrical analysis was performed. To this end, a 4.85 mm diameter circular area 
was superimposed on the bone defect area as the region of interest (ROI; Figure 2). 
Digital images were recorded, after which the bone and CPC area were quantified 
by color recognition using image analysis techniques (Leica Qwin Pro-image 
analysis system, Wetzlar, Germany).
2.6 Statistical analysis
All statistical analyses were performed with GraphPad Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA, USA). Significant differences between 
the groups were determined using analysis of variance (ANOVA). A Tukey-Kramer 
(multiple comparison) test was used to identify significant differences between 
the means of the various experimental groups at different implantation periods. 
Results were considered significant at p < 0.05 and depicted as a single asterisk (*).
Figure 2   Region of interest (ROI) for histomorphometrical measurements.
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3. RESULTS
3.1 Setting time of CPC
It was observed that the initial and final setting times (Table 2) of α-TCP-based 
CPC without PLGA microparticles (CPC-CMC) were close to those of HydroSet. 
Incorporation of PLGA into CPC-CMC shortened the initial setting time (3.3 minutes), 
but prolonged the final setting time (16 minutes) as compared to the other two 
experimental groups.
3.2 Pre-clinical observations
All 36 animals recovered uneventfully from the surgical procedure and remained 
in good health for the first 4 weeks. No signs of wound complications were 
observed post-operatively. After 12 weeks of implantation, one animal died due 
to influenza, whereas the rest of the animals remained in good health. After 
26 weeks of implantation, three animals died due to influenza (without any 
correlation to the implantation of the CPCs), while the other 9 animals were still 
healthy. At the end of the different implantation periods, a total of 64 implants 
were harvested (24 implants after 4 weeks, 22 implants after 12 weeks and 
18 implants after 26 weeks).
3.3 Descriptive light microscopy
3.3.1 Descriptive light microscopy of PMMA sections
Representative histological images after 4 weeks of implantation are depicted in 
Figure 3. All CPCs revealed a full filling of the defect and an intact morphology 
without any apparent signs of CPC degradation or bone ingrowth into the 
implant. For both CPC-CMC and HydroSet, the edges of the created defect were 
still clearly recognizable, whereas a rougher morphology along the implant 
edges was observed for CPC-CMC-PLGA. For the CPC-CMC and CPC-CMC-PLGA 
groups, an interfacial zone of lower staining intensity was observed between 
Table 2  
CPC Initial setting time (min) Final setting time (min)
CPC-CMC 4.9 ± 0.8 8.9 ± 1
CPC-CMC-PLGA 3.3 ± 0.2 16 ± 0.5
HydroSet1 4.5 8.5
1 Obtained from the manufacturer’s product data sheet
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bone tissue and the interior of the implant (Figure 3, indicated with asterisk). 
For all experimental groups, a tight contact between bone tissue and the implants 
was observed without the presence of an intermediate fibrous tissue layer.
After an implantation period of 12 weeks, the morphological characteristics of 
CPC-CMC and HydroSet specimens were similar to their appearance after 
4 weeks of implantation (Figure 4). An interfacial zone of lower staining intensity 
was observed  and a tight contact between bone and the implants was observed 
along the defect border. No evidence was found for bone ingrowth into the 
implant. In contrast, the CPC surface was considerably irregular due to CPC 
degradation and concomitant bone formation was observed along the peripheral 
area of the CPC-CMC-PLGA specimens, which corresponds to the initiation of a 
bone remodeling process. 
At the longest study period of 26 weeks, CPC degradation was evident both at the 
surface and interior of CPC-CMC-PLGA implants, while abundant new bone 
formation was clearly observed in the areas where CPC was degraded. The 
newly formed bone displayed a cancellous structure, which resembled the 
structure of the pristine bone in the vicinity of the defect location. These implant 
characteristics indicated that degradation of PLGA microparticles induced the 
formation of a porous CPC structure, which allowed for ingrowth of newly 
Figure 3   Representative histological sections after 4 weeks of implantation. 
LM: low magnification, scale bar = 1mm; HM: high magnification, 
scale bar = 200 µm. B = bone, C = CPC and * = interfacial zone.
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formed bone throughout the implant. On the other hand, slow CPC degradation 
was observed for PLGA-free CPC-CMC and HydroSet implants. Degradation of 
the implant’s peripheral area was minimal and new bone formation only 
occurred at the implant periphery. A tight bone-to-implant contact was observed 
for all experimental groups. Similar to previous time points, an interfacial zone 
of lower staining intensity could still be observed in the CPC-CMC group. 
However, this interfacial zone was less clear for the CPC-CMC-PLGA group due to 
degradation of the CPC and the corresponding loss of implant integrity (Figure 5).
  
3.3.2 Descriptive light microscopy of paraffin sections
No inflammatory cells were observed in the paraffin sections stained with 
hematoxylin and eosin, while TRAP-positive osteoclasts or osteoclast-like cells 
were only observed for the CPC-CMC-PLGA group after 26 weeks of implantation, 
albeit in negligible quantities (data not shown). EVG-stained paraffin sections 
allowed the identification of collagen in bone tissue (Figure 6; stained in red). 
For CPC-CMC, a layer of bone was clearly observed around the implants, and a 
thicker bony layer was observed after 12 weeks of implantation. For CPC-CMC- 
PLGA, limited bone formation was observed after 4 weeks of implantation, 
but the amount of bone formation increased considerably with increasing 
Figure 4   Representative histological sections after 12 weeks of implantation. 
LM: low magnification, scale bar = 1mm; HM: high magnification, 
scale bar = 200 µm. B = bone, C = CPC and * =interfacial zone.
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implantation time to 12 and 26 weeks. Abundant bone formation was observed 
both along the implant surface and throughout the interior of the CPC-CMC-PLGA 
implants. Acellular layers of up to several hundreds of micrometers were 
observed between the implant perimeter and bone tissue for CPC-CMC and 
CPC-CMC-PLGA implants. For HydroSet, a thin layer of bone was observed at 
the interface between cement and native bone tissue. The thickness of this layer 
gradually increased with implantation time, indicating that the formation of 
bone continued for the entire study period.
3.4 Histomorphometry
3.4.1 CPC degradation
A quantitative evaluation of the amount of CPC degradation after 4, 12 and 
26 weeks of implantation is shown in Figure 7. Obviously, the overall degradation 
of CPC was negligible for all implantation periods for CPC-CMC and HydroSet, 
but not for CPC-CMC-PLGA. For CPC-CMC-PLGA, CPC degradation increased with 
implantation time. After the longest implantation period of 26 weeks (Figure 7c), 
the amount of remaining CPC was significantly lower (p < 0.001) for CPC-CMC- 
PLGA (59.1 ± 5.6%) compared to CPC-CMC (87.0 ± 7.5%) and HydroSet (91.9 
± 4.9%), respectively.
Figure 5   Representative histological sections after 26 weeks of implantation. 
LM: low magnification, scale bar = 1mm; HM: high magnification, 
scale bar = 200 µm. B = bone, C = CPC and * =interfacial zone.
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3.4.2 Bone formation
Quantitative evaluation of the amount of bone formation after 4 weeks 
implantation revealed significantly more bone formation around CPC-CMC-PLGA 
compared to HydroSet (Figure 7d; p < 0.05). After 12 weeks of implantation, 
a similar significant difference between these groups was observed. At the 
longest implantation period (26 weeks; Figure 7f), a significantly higher amount 
of bone formation was observed for CPC-CMC-PLGA (6.5 ± 1.8 %) compared to 
CPC-CMC (1.1 ± 1.0 %; p < 0.001) and HydroSet (0.7 ± 0.7%; p < 0.001). In contrast, 
bone formation did not increase as a function of implantation time for CPC-CMC 
and HydroSet (Figures 7d-f).
Figure 6   Histological morphology of in vivo bone formation (EVG staining, 
paraffin sections, B = bone, C = CPC and * = acellular layer), scale bar 
= 200 µm.
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4. DISCUSSION
The current study focused on the long-term evaluation of the in vivo degradation 
behavior of three apatite-forming CPCs. An α-TCP-based formulation containing 
CMC as cohesion promotor and PLGA microparticles as acid-producing porogens 
(CPC-CMC-PLGA) was compared to a PLGA-free, α-TCP-based CPC formulation 
containing CMC (CPC-CMC), while the commercially available HydroSetTM was 
included in the study design as control to compare the degradation behavior of 
Figure 7   Histomorphometrical analysis of CPC and bone volume in ROI of  
the three implanted CPCs after 4, 12 and 26 weeks of implantation 
(n=7 for 4 weeks and 6 weeks, n = 5 for 26 weeks, error bars 
represent standard deviation).
(a)
(c)
(e)
(b)
(d)
(f)
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the two experimental CPCs to a clinically applied CPC. The results showed that 
all CPCs were osteoconductive, as confirmed by the formation of a tight contact 
between bone tissue and the implant surface. CPC-CMC and HydroSet cements 
showed only marginal degradation at the periphery, whereas almost half of the 
original CPC-CMC-PLGA cement volume was degraded after 26 weeks of 
implantation with concomitant bone formation throughout the entire defect 
area.
In agreement with our hypothesis, the incorporation of PLGA microparticles 
resulted into an acceleration of CPC degradation and formation of new bone 
tissue compared to the other experimental groups. Generally, PLGA degrades by 
hydrolysis into lactic and glycolic acid monomers. As a consequence, the 
degradation of PLGA microparticles not only resulted into the formation of 
macropores that allowed for bone ingrowth, but also created a sufficiently acidic 
microenvironment that accelerated the dissolution of the CPC matrix.15-17 This 
process was recently shown to depend on various parameters such as the 
molecular weight, composition and end-group functionalization of the polymer 
as well as the morphology of the microparticles.14,18 A previous study from our 
group tested the in vivo degradation behavior of a CPC formulation containing 
spherical microparticles of the same type of PLGA and size (~50 μm), 
a comparable amount of dense acid-terminated PLGA microparticles (46 wt% 
vs. 39 wt% as employed in the current study) and a similar animal model.14 
This study revealed that the PLGA-containing CPCs lost their integrity after 
6 weeks and were almost completely degraded after only 12 weeks of 
implantation (30% of remaining cement volume). In the current study, however, 
it was observed that PLGA-containing cements disintegrated to a much lesser 
extent after 12 weeks of implantation (66 ± 13% of remaining cement volume), 
and were degraded only partially after 26 weeks (59 ± 6% of remaining cement 
volume left). In addition, the amount of new bone formation after 26 weeks in 
the current study (7 ± 2%) was considerably lower than values reported 
previously after 12 weeks (56%).14
Obviously, the degradation rate of the PLGA-containing CPC tested herein was 
considerably lower than reported previously. These differences in in vivo 
degradation behavior can be attributed to several differences in the composition 
of the tested CPC formulations. First, the current CPC formulation contained 
α-TCP as single ceramic precursor phase, while the previously tested CPC 
contained considerable amounts of a calcium phosphate precursor phase of 
higher solubility, i.e. 10 wt% of dicalcium phosphate anhydrous (monetite). 
Moreover, previously tested formulations did not contain CMC as cohesion 
promotor, whereas 1.5 wt% of the powder phase consisted of CMC in the current 
study.
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The difference in degradation behavior between the previous14 and current 
implantation studies in the femoral condyle was also noticeable in Figure 5, 
where acellular layers were observed between bone tissue and the original CPC 
implant surface in the decalcified and EVG-stained paraffin sections. These 
acellular layers were not observed around the CMC-free HydroSet control 
specimens. As a consequence, the formation of these acellular layers might be 
caused by either the incorporation of CMC or the different composition of the 
calcium phosphate phase (monophasic α-TCP vs. a mixture of tetracalcium 
phosphate and dicalcium phosphate dehydrate). Interestingly, this acellular 
layer had a porous structure in the CPC-CMC-PLGA samples, whereas a more 
dense morphology was observed for the acellular layer surrounding CPC-CMC 
samples. This observation seems to indicate that PLGA microparticles were 
entrapped in the acellular layer in the course of the study period, thereby causing 
the formation of the porous structure in the acellular layer after degradation of 
the PLGA microparticles. We speculate that this acellular layer was formed due 
to water absorption and subsequent swelling of the CMC upon mixing with the 
aqueous phase, which might have caused an outward pressure that induced the 
formation of a CMC-rich capsule around the CPC implants. This capsule could 
have compromised the osteoconductivity of the CPC and hampered the diffusion 
of aqueous body fluids into the CPC interior. Since influx of body fluids is a 
prerequisite for the hydrolytic degradation of the PLGA microparticles, such an 
protective CMC capsule would also reduce the degradation of PLGA microparticles 
and hence the CPC matrix. In addition, Koulourides et al. reported that CMC is a 
hydroxyapatite growth inhibitor,19 which might have contributed to delayed 
hardening of the CPC toward the apatite phase, thereby reducing the osteocon-
ductivity of the CMC-containing CPC formulations.
In order to confirm the above-mentioned explanation for the reduced rates of 
CPC degradation and bone ingrowth into CPC-CMC and CPC-CMC-PLGA as 
compared to previous in vivo studies, future work will focus on the in vivo 
evaluation of CMC-free and CMC-containing α-TCP-based cements in a similar 
femoral condyle animal model.
5. CONCLUSIONS
CPCs containing CMC as cohesion promotor and PLGA microparticles as porogens 
were able to induce partial degradation of apatite-forming CPCs and concomitant 
replacement by bone tissue.
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SUMMARY 
The general aim of the research described in this thesis was to study the process 
of calcium phosphate cement degradation and replacement by bone tissue. 
Calcium phosphate cements (CPCs) are an emerging class of synthetic bone 
substitutes which exhibit strong chemical similarity to the mineral phase of 
bone and teeth. CPCs are injectable and moldable due to their in situ self-setting 
properties, which render this class of synthetic bone substitutes highly suitable 
for specific applications in dentistry and orthopedics. Unfortunately, CPCs 
degrade slowly in vivo, which impedes subsequent replacement of the synthetic 
biomaterials with newly-formed bone tissue. To increase the degradation rate of 
CPCs, polymeric porogens can be introduced into the cement matrix to induce 
the formation of macroporosity, which facilitates the ingrowth of newly formed 
bone tissue. Nevertheless, the kinetics and mechanism of the degradation of 
CPCs containing polymeric porogens are not yet fully understood. Therefore, the 
process of calcium phosphate cement degradation and subsequent replacement 
by bone tissue was studied in more detail.
In chapter 2, the clinical performance of injectable CPCs for craniomaxillofacial 
applications was critically reviewed based on the use of CPCs in clinical trials 
since 1980. Generally, a positive outcome was reported for the application of 
CPCs in non-load-bearing skeletal sites such as the crianiofacial region in view of 
the evident esthetic advantages caused by the less invasive application procedure 
for CPCs. However, the evidence for successful application of CPCs was not 
unambiguously confirmed for all clinical indications. Consequently, prospective 
long-term clinical studies are needed to obtain insight in the long-term behavior 
of CPC in human patients. These clinical studies should be the basis for further 
improvement of the mechanical and biological properties of CPCs.
In order to accelerate the degradation rate of CPCs, chapter 3 focused on the 
incorporation of polymeric microspheres composed of either poly(lactic-co- 
glycolic acid) (PLGA), gelatin or poly(trimethylene carbonate) (PTMC) into 
calcium phosphate cement. The in vitro degradation kinetics and the in vivo 
safety of the resulting composites were evaluated by in vitro immersion tests 
and a subcutaneous implantation study in rabbits, respectively. After retrieval 
of the explants, specimens were analyzed physicochemically and histologically. 
The results showed that all microsphere-enriched CPCs revealed microsphere 
degradation after 12 weeks of subcutaneous implantation, which caused a 
decrease of the compression strength of the explants. The PLGA microspheres 
exhibited bulk erosion simultaneously throughout the entire composite, whereas 
the gelatin type B microspheres were degradated from the outside to the center 
of the composite. High molecular weight PTMC microspheres exhibited surface 
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erosion resulting in decreasing microsphere size. Furthermore, all composites 
showed a similar tissue response characterized by a decreasing capsule thickness 
over time and a persistent moderate inflammatory response at the implant 
interface. The study indicated that microsphere-enriched CPCs can be used to 
generate porous scaffolds in situ after degradation of microspheres by various 
degradation/erosion mechanisms.
In chapter 4, the in vivo degradation properties and osteocompatibility of 
injectable calcium phosphate cement (CPC) with or without polyester micro - 
spheres (~50 vol%) were evaluated. Three types of spheres were assessed, i.e., 
poly(lactic-co-glycolic acid) (CPC/PLGA), gelatin (CPC/GEL) and poly(trimethylene 
carbonate) (CPC/PTMC). After 4, 8 and 12 weeks of implantation, specimens 
were retrieved and analyzed using histological and histomorphometrical methods. 
Results showed that porogen-free CPCs showed excellent bone contact but only 
very limited erosion at the surface. CPC/PLGA implants degraded almost 
completely, while the general tissue response improved at each time period. 
CPC/PTMC showed slower degradation kinetics compared to CPC/PLGA. The 
degradation properties of the CPC/PLGA microspheres composite and its bone 
response upon implantation into the femoral condyles of rabbits were significantly 
better than those of CPC/gelatin and CPC/PTMC microspheres composites.
In chapter 5, the effect of PLGA microsphere diameter on bone formation after 
injection of PLGA-enriched calcium phosphate cement (CPC/PLGA) was 
evaluated using a guinea pig tibial intramedullarly model. Injectable CPC/PLGA 
formulations were prepared using PLGA microspheres with either a small (25 
μm) or large (100 μm) diameter, which were incorporated at a 20:80 ratio (wt%) 
into apatite-forming CPC. Both CPC/PLGA formulations were injected into the 
marrow-ablated tibial intramedullary cavity, while histological and histomor-
phometrical techniques were used to evaluate the process of bone formation 
after an implantation period of 12 weeks. The results demonstrate that the 
dimensions of PLGA microspheres within injectable CPC/PLGA had a strong 
effect on bone formation. Whereas both small (25 μm) and large (100 μm) 
microspheres allowed bone ingrowth throughout the CPC matrix, a two-fold 
higher amount of newly formed bone was observed for CPC/PLGA with small 
PLGA microspheres within the CPC matrix. Additionally, the pattern of bone and 
marrow formation showed distinct differences related to PLGA microsphere 
size. In general, this study demonstrates that incorporation of PLGA microspheres 
with a diameter of 25 μm resulted into the formation of pores of 25 μm within 
the CPC, which was sufficient to allow for substantial amounts of bone ingrowth. 
Further, the results demonstrate that the diameter of PLGA microspheres can be 
used as tool to control the rates of CPC degradation and subsequent bone 
formation for injectable CPC/PLGA bone substitutes.
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In chapter 6, the long-term degradation behavior of two types of α-tricalcium 
phosphate-based apatite-forming CPCs was compared to a commercially available 
apatite-forming cement, i.e., Hydroset. Carboxyl methylcellulose (CMC) was used 
as cohesion promotor to improve handling properties of the two experimental 
cements, whereas poly(lactic-co-glycolic acid) (PLGA) microparticles were added 
to introduce macroporosity and stimulate CPC degradation. All three CPCs were 
injected into defects drilled into rabbit femoral condyles and explanted after 4, 
12 or 26 weeks, after which the bone response was assessed both qualitatively 
and quantitatively. The study indicated that CPCs without PLGA microparticles 
degraded only at the periphery of the implants, as reflected by a residual CPC 
volume of ~90%. The PLGA-containing CPC degraded significantly faster than 
the PLGA-free groups, as characterized by a residual CPC volume of approximately 
55% after 26 weeks of implantation. It was shown that the long term degradation 
of CPC containing CMC and PLGA was superior to PLGA-free CPC by inducing 
partial degradation of apatite-forming CPCs and concomitant replacement by 
bone tissue.
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CLOSING REMARKS AND FUTURE PERSPECTIVES
It is generally recognized that an ideal bone substitute should degrade and be 
replaced by bone simultaneously without evoking any adverse events such as 
infection upon implantation into the human body. In the current thesis, several 
in vivo experiments have been performed to study the influence of the 
incorporation of polymeric porogens on the degradation behavior of injectable 
self-setting calcium phosphate cement matrices. The results of the current 
thesis confirm that the rate of CPC degradation and bone ingrowth strongly 
depend on the physicochemical characteristics of the incorporated polymeric 
porogens composed of either PLGA, PTMC or gelatin.
From an materials engineering point of view, the physicochemical properties of 
PLGA microparticles were most suitable to allow for control over the in vivo 
degradation kinetics of both CPC and PLGA as well as the general tissue response. 
In contrast to the enzymatic degradation pathway for PTMC and gelatin, PLGA 
porogens degrade hydrolytically. Since the hydrolytic degradation of PLGA does 
not depend on diffusion of enzymes into the interior of cement composites, the 
degradation kinetics of incorporated PLGA microparticles were independent 
from the distance to the implant surface. In addition, the degradation by-products 
of PLGA are acidic monomers lactic and glycolic acid. These acidic monomers 
increase the degradation rate of the surrounding CPC matrix since calcium 
phosphates dissolve under acidic conditions.
In chapter 4 of the current thesis, degradation of the PLGA microspheres lasted up 
to several months, which was relatively slow as compared to studies performed by 
Lanao et al. [1], who observed that degradation of PLGA microspheres strongly 
depends on physicochemical parameters such as end-group functionalization, 
molecular weight as well as microparticle morphology (dense vs. hollow). 
By optimizing these physicochemical properties, Lanao et al. observed that acid- 
terminated PLGA degraded much faster than ester end-capped PLGA, while 
dense PLGA microspheres generated more acid by-products upon hydrolytic 
degradation than hollow microspheres [1]. Consequently, the slow degradation 
as observed in chapter 4 was most likely caused by the use of hollow microspheres 
composed of slow-degrading ester end-capped PLGA microspheres. Therefore, 
dense PLGA microparticles composed of acid-terminated PLGA were used in the 
last chapter of this thesis (chapter 6) to accelerate the degradation of CPCs, 
aiming at complete degradation of both CPC and PLGA after 26 weeks of 
implantation. However, the incorporation of these PLGA microparticles induced 
only partial rather than the desired complete degradation of the cement 
composites after 26 weeks which was attributed to a potential delaying effect of 
the cohesion promotor CMC on the degradation of CPCs containing both PLGA 
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microparticles and CMC. Therefore, future studies should focus on elucidation of 
the effect of CMC on the in vitro and in vivo degradation of CPCs containing both 
PLGA and CMC.
Although the degradation of PLGA-containing CPCs can be tuned to a certain 
extent, degradation of these composites still takes several weeks to months due 
to the relatively slow degradation rate of PLGA. Therefore, alternative organic 
porogens should be explored to allow the creation of porosity during setting of 
the cement, thereby allowing for ingrowth of bone tissue much earlier after 
implantation. To this end, sugar crystals might be highly suitable candidate materials 
in view of their fast degradation and harmless degradation by- products. 
Consequently, future research should focus on development of CPCs enriched 
with (combinations of) PLGA and sugar particles.
Regarding upscaling, it should be emphasized that industrial production of 
PLGA microspheres is expensive, whereas the use of cryogenically milled PLGA 
microparticles (as employed in chapter 6) is much more attractive from a 
commercial point of view due to the low costs. Future research should focus on 
the optimization of the amount, size and size distribution of cryogenically milled 
PLGA microparticles.
From a clinical perspective, the results of this thesis confirm the suitability of 
PLGA-containing CPC cements to facilitate bone regeneration in non-load-bear-
ing skeletal sites. Nevertheless, it should be emphasized that the majority of 
bone regenerative treatments involves bone grafting procedures in load-bearing 
sites. Since the load-bearing capacity of calcium phosphate cements is poor due 
to the intrinsic brittleness of bioceramics, future research should focus on 
combining the application of PLGA-containing CPCs with additional fixation such as 
strong, tough and preferably resorbable frames and meshes for the application 
in e.g. large full-thickness cranial defects. Alternatively, load-bearing cements 
should be improved by incorporation of reinforcing phases such as polymeric 
fibers or bioceramic whiskers. In such way, bone ingrowth can be stimulated by 
maintaining shape conformity without causing long-term complications such as 
deformation of the implant and asepsic inflammation.
Since inflammation is a serious clinical complication, the degradability of PLGA- 
containing CPCs offers the opportunity to design injectable bone substitute 
materials which facilitate local, controlled and sustained release of antibacterial 
agents such as antibiotics or antimicrobial peptides in order to treat infectious 
bone defects or periodontitis and prevent bacterial colonization upon tooth 
socket preservation. Generally, however, extensive and properly designed 
clinical trials should be carried out before such drug-loaded calcium phosphate 
cements can be clinically applied.
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SAMENVATTING
Het algemene doel van het onderzoek beschreven in dit proefschrift was het 
bestuderen van het degradatieproces van calciumfosfaat cement (CPC) en de 
vervanging door botweefsel. Calciumfosfaat cement vormt een opkomende 
klasse van synthetisch bot substituten, die een sterke chemische gelijkenis 
vertonen met de minerale fase van bot en tanden. CPC’s zijn injecteerbaar en 
vormbaar vanwege hun in-situ uithardende eigenschappen, waardoor deze 
klasse van synthetisch bot substituten uitermate geschikt zijn voor specifieke 
toepassingen in de tandheelkunde en orthopedie. Helaas, verloopt de in-vivo 
degradatie van CPC’s te langzaam, waardoor de vervanging van de synthetische 
biomaterialen met nieuwgevormd botweefsel wordt belemmerd. Het versnellen 
van de CPCs degradatie wordt verkregen door het toevoegen van polymeren 
porievormers, hierdoor ontstaat een macroporositeit in de cement matrix, 
hierdoor wordt de ingroei van nieuw gevormde botweefsel vergemakkelijkt. 
Desalniettemin is de kinetiek en het mechanisme van de afbraak van de CPC’s 
met polymeren porievormers nog niet volledig begrepen. Daarom is het 
degradatie proces van calciumfosfaat cement en de vervanging/ingroei door 
botweefsel in detail bestudeerd.
In hoofdstuk 2, werd een literatuur studie uitgevoerd, waarbij het klinische 
gedrag van injecteerbaar CPC’s voor cranio-maxillofaciale toepassingen 
beoordeeld op basis van klinische studies sinds 1980. Over het algemeen werd 
een positief resultaat voor de toepassing van de CPC’s op onbelaste delen van het 
skelet gemeld, CPC’s toegepast in de crianio-faciale-regio hebben duidelijk 
esthetische voordelen, hetgeen vooral wordt veroorzaakt door de minder 
invasieve operatie procedure voor CPC’s. Echter, overduidelijk bewijs voor 
succesvolle toepassing van CPC’s voor alle klinische indicaties werd niet 
ondubbelzinnig bevestigd. Daarom zijn prospectieve lange termijn klinische 
studies nodig om meer inzicht te verkrijgen in de lange termijn werking van CPC 
in humane patiënten. Deze klinische studies moeten de basis vormen voor 
verdere verbetering van de mechanische en biologische eigenschappen van 
CPC’s.
Om de degradatie snelheid van de CPCs te verhogen, werd in hoofdstuk 3 de 
incorporatie van polymere microsferen samengesteld uit poly (melkzuur-co- 
glycolic zuur) (PLGA), gelatine of poly(trimethylene carbonate) (PTMC) in 
calciumfosfaat cement bestudeerd. De in-vitro degradatie kinetiek en in-vivo 
veiligheid van de gevormde composieten werden respectievelijk bestudeerd 
door een in-vitro incubatietest en een subcutane implantatie studie bij konijnen. 
Fysisch-chemische en histologische analyse lieten zien dat alle geïncorporeerde 
polymere microsferen in het CPC degradeerde na 12 weken subcutane implantatie, 
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met als gevolg een afname van de druksterkte van alle polymeer/CPC composiet 
materialen. De PLGA microsferen lieten een bulk erosie in het gehele composiet 
scaffold zien, terwijl de gelatine type B microsferen degradeerden vanaf buiten 
naar binnen in het scaffold. De PTMC microsferen vertoonde een oppervlakte 
erosie, dit resulteerde in de afname van de grootte van de polymere microsfeer. 
Verder liet histologische analyse zien dat alle polymere composieten eenzelfde 
weefselreactie vertoonde, gekenmerkt door een afnemende capsule dikte in de 
tijd en een milde ontstekingsrespons aan het implantaatoppervlak. Uit dit onderzoek 
is gebleken dat polymere microsferen geïncorporeerd in CPC’s kunnen worden 
gebruikt voor het genereren van poreuze scaffolds en de degradatie van deze 
microsferen verloopt via verschillende afbraak/erosie mechanismen.
In hoofdstuk 4, werd de in-vivo degradatie en de osteocompatibiliteit van 
injecteerbaar calciumfosfaat cement (CPC) met of zonder polyester microsferen 
(~ 50 vol %) geëvalueerd. Drie soorten polymere microsferen werden bestudeerd, 
poly (melkzuur-co-glycolic zuur) (PLGA), gelatine (GEL) en poly(trimethylene 
carbonate) (PTMC). Na een implantatie periode van 4, 8 en 12 weken werden de 
samples uitgenomen en geanalyseerd met behulp van histologie en histomor-
fometrie. De resultaten demonstreerde dat poriën-vrije CPCs een uitstekend bot 
contact liet zien, met een zeer beperkte erosie aan het implantaatoppervlakt. 
Daarentegen degradeerden de CPC/PLGA composieten bijna volledig. Verder 
werd waargenomen dat CPC/PTMC composieten langzamer degradeerden in 
vergelijk met CPC/PLGA. Uit deze studie bleek ook dat de degradatie van CPC/
PLGA composieten en de bot reactie na implantatie in het femorale condyl van 
konijnen aanzienlijk beter waren in vergelijk met CPC/gelatine- en CPC/PTMC 
composieten. 
In hoofdstuk 5 is het effect van de afmeting van PLGA microdeeltjes op bot-
regeneratie onderzocht na injectie van calciumfosfaat cement (CPC)/PLGA in het 
beenmerg van de scheenbenen van cavia’s. Hiertoe werden injecteerbare CPC/
PLGA formuleringen gemaakt van PLGA microsferen met een kleine (~25 μm) of 
grote (~100 μm) diameter. Deze microsferen werden vervolgens in een 20/80 
gewichtsratio vermengd met het CPC. Na verwijdering van het beenmerg zijn 
beide CPC/PLGA formuleringen geïnjecteerd in de beenmergholte. Na een 
 implantatieperiode van 12 weken zijn histologie en histomorfometrie gebruikt om 
botvorming te bestuderen. De resultaten lieten voor beide CPC/PLGA formuleringen 
zien dat na degradatie van de PLGA microsferen botweefsel gevormd was in de 
ontstane poriën. De CPC/PLGA formulering met kleine (~25 μm) afmeting 
microsferen bevatte twee keer zoveel botweefsel. Ook was het patroon van 
bot- en mergvorming afhankelijk van de afmetingen van de PLGA microdeeltjes. 
In het algemeen bewees deze studie dat PLGA microsferen van ~25 μm, die 
leidden tot poriën van ~25 μm in CPC, voldoende groot waren voor botingroei en 
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substantiële botvorming. Bovendien lieten de resultaten zien, dat PLGA microsfeer 
afmeting een middel is om de mate van botvorming te sturen in injecteerbare 
CPC/PLGA botvervangers.
In hoofdstuk 6, werd de lange termijn degradatie van twee typen apatiet- 
vormend CPCs vergeleken met een commercieel beschikbaar apatiet-vormend 
cement (Hydroset). Om de verwerkingseigenschappen te verbeteren werd carboxy - 
methylcellulose (CMC) gebruikt als bindmiddel bij de twee experimenteel 
cementen, terwijl poly (melkzuur-co-glycolic zuur) (PLGA) deeltjes werden 
toegevoegd om macroporositeit te introduceren en daarmee de degradatie van 
de CPC te stimuleren. De drie CPCs werden geïnjecteerd in defecten gemaakt in 
de femorale condyle van konijn. Na een implantatieperiode van 4, 12 en 26 
weken, werden de CPC/PLGA composieten geëxplanteerd en werd het botrespons 
zowel kwalitatief als kwantitatief beoordeeld. Uit deze studie is gebleken dat 
CPC zonder PLGA microsferen alleen degradeerde aan de buitenzijde van het 
implantaat, waarbij het resterende CPC volume ongeveer 90% bedroeg. 
Daarentegen degradeerden de CPC/PLGA composieten aanzienlijk sneller, na 
een implantatieperiode van 26 weken was het resterende CPC volume ongeveer 
55%. Geconcludeerd kan worden dat de lange termijn degradatie van CPC met 
CMC en PLGA significant meer botvorming laat zien in vergelijk met PLGA vrije 
CPC, vooral veroorzaakt door de vorming van zure afbraakproducten van PLGA, 
deze afbraakproducten versnellen de degradatie van apatiet-vormende CPCs en 
gelijktijdige ingroei door botweefsel.
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Algemeen wordt erkend dat een ideale botvervanger moet degraderen en 
gelijktijdig wordt vervangen door bot zonder bijwerkingen zoals een infectie na 
implantatie in het menselijk lichaam. In dit proefschrift zijn verschillende in-vivo 
experimenten uitgevoerd, hiermee werd het effect bestudeerd van de invloed 
van geïncorporeerde polymere porievormers op de degradatie van injecteerbaar 
in-situ uithardend calciumfosfaat cement matrices. De resultaten bevestigen dat 
de snelheid van de CPC-afbraak- en bot ingroei sterk afhankelijk is van de fy-
sisch-chemische eigenschappen van de geïncorporeerde polymere porievormers, 
bestaande uit PLGA, PTMC of gelatine. Vanuit een materiaalkundig oogpunt, zijn 
de fysisch-chemische eigenschappen van PLGA microsferen het meest geschikt 
om de in-vivo degradatie kinetiek van zowel CPC en PLGA te optimaliseren. In 
tegenstelling tot de enzymatische afbraak mechanisme voor PTMC en gelatine 
degraderen PLGA porievormers hydrolytisch. Als gevolg van de hydrolyse van 
PLGA worden zure monomeren (melkzuur en glycolzuur) gevormd, deze zure 
monomeren versnellen de degradatie van de omliggende CPC-matrix. 
In hoofdstuk 4 van dit proefschrift, werd waargenomen dat degradatie van 
PLGA microsferen enkele maanden duurde, dit is relatief traag vergeleken met 
studies van Lanao et al. [1], in deze studies werd gevonden dat de degradatie 
snelheid van PLGA microsferen sterk afhankelijk was van fysisch-chemische 
parameters zoals functionaliseren van de eindgroep , molecuulgewicht alsmede 
de morfologie van de microsferen (dicht vs. hol). Door het optimaliseren van 
deze fysisch-chemische eigenschappen vonden Lanao et al. een versnelde 
degradatie van PLGA met zure-eindgroepen in vergelijk met PLGA met es-
ter-eindgroepen, verder produceren dichte PLGA microsferen zuurdere 
bijproducten tijdens de hydrolytische afbraak dan holle PLGA microsferen [1]. 
Aangenomen kan worden dat de langzame degradatie van de PLGA microsferen 
veroorzaakt wordt door het gebruik van holle microsferen gesynthetiseerd uit 
langzaam afbrekende PLGA microsferen met ester eindgroepen (hoofdstuk 4). 
Daarom werd in hoofdstuk 6 van dit proefschrift een lange termijn in-vivo 
experiment uitgevoerd met dichte PLGA microsferen met zure-eindgroepen, om 
zodoende na een implantatie periode van 26 weken een volledige degradatie van 
zowel CPC en PLGA microsferen waar te nemen. De incorporatie van deze PLGA 
microdeeltjes induceerde slechts gedeeltelijk in plaats van de gewenste volledige 
afbraak van de cementcomposiet na 26 weken, dit werd toegeschreven aan een 
potentieel vertragend effect van de cohesie promotor CMC op de afbraak van 
CPC’s bevattende CMC/PLGA microdeeltjes. Daarom moeten toekomstige 
studies zich richten op het effect van CMC tijdens de in-vitro en in-vivo afbraak 
van CPC/PLGA/CMC composieten.
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Hoewel de afbraak van CPC/PLGA composieten kunnen worden getuned, zal de 
afbraak van deze composieten nog enkele weken tot maanden duren, dit wordt 
vooral veroorzaakt door de relatief langzame degradatiesnelheid van PLGA 
microsferen. Daarom is het aan te raden om alternatieve organische porievormers 
te onderzoeken, waardoor de ingroei van botweefsel in het composiet veel 
eerder kan plaatsvinden. Een zeer geschikt kandidaat-materiaal zijn suiker-
kristallen mede gezien hun snelle afbraak zonder schadelijke bijproducten. 
Daarom moet toekomstig onderzoek zich richten op de ontwikkeling van de 
CPCs verrijkt met combinaties van PLGA en suiker deeltjes
Ten aanzien van schaalvergroting, moet worden benadrukt dat de industriële 
productie van PLGA microsferen duur is, terwijl het gebruik van cryogeen 
gemalen PLGA microdeeltjes (zoals toegepast in hoofdstuk 6) veel aantrekkelijker 
is vanuit een commercieel oogpunt tengevolge van de lage kosten. Toekomstig 
onderzoek moet zich daarom richten op het optimaliseren van de hoeveelheid, 
de grootte en grootteverdeling van cryogeen gemalen PLGA microdeeltjes.
Vanuit een klinisch oogpunt blijkt dat de resultaten beschreven in dit proefschrift, 
de toepasbaarheid van CPC/PLGA cement bevestigen en botherstel in niet- 
dragende skeletplaatsen vergemakkelijken. Toch moet worden benadrukt dat de 
meerderheid van de bot regeneratieve behandelingen zoals bottransplantatie 
worden uitgevoerd bij dragende skeletplaatsen. Aangezien de breuktaaiheid van 
calciumfosfaat cement laag is, moet toekomstig onderzoek zich richten op het 
combineren van de toepassing van CPC/PLGA composieten voorzien van extra 
fixatie zoals sterke, taaie en bij voorkeur resorbeerbare frames en meshes voor 
de toepassing bij grote craniale defecten. Een alternatief is om deze cementen te 
versterkende met polymeervezels of biokeramische deeltjes. Zodoende kan 
botingroei worden gestimuleerd, waardoor de implantaatvorm wordt behouden, 
zonder het veroorzaken van lange termijn complicaties zoals vervorming van 
het implantaat en aseptische  ontsteking.
Aangezien ontstekingen ernstige klinische complicatie zijn, geven degradeerbare 
CPC/PLGA composieten de mogelijkheid om injecteerbare botvervangende 
materialen te ontwerpen met lokale gecontroleerde en langdurige afgifte van 
antibacteriële middelen zoals antibiotica of antimicrobiële peptiden. Hiermee 
worden infecties bij botdefecten of parodontitis behandeld en het voorkomen 
van bacteriële groei in alveolair bot. In het algemeen moeten uitgebreide en goed 
ontworpen klinische onderzoeken worden uitgevoerd, voordat dergelijke met 
geneesmiddelen beladen calciumfosfaat cementen klinisch kunnen worden 
toegepast. 
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